var data = [
  {
      "molecule_name": "ABP 215",
      "status_text": "Active in Development",
      "stage_text": "Biosimilar",
      "tile_icon": "igg1kappa.svg",
      "alternate_names": "Anti-VEGFAntibody, bevacizumab(Avastin®)biosimilar",
      "molecule_illustration": "abp215.png",
      "pstformed": "",
      "pstraw": "0",
      "class1": "IgG1",
      "class2": "Kappa LC",
      "modality": "Monoclonal Antibody",
      "extinctioncoeff": "1.7",
      "peptidemw": "146,307",
      "pi": "8.3",
      "summary_text": "Based on the putative structure of IgG1 antibodies, the protein is composed of two heavy chains, and two light chains.  There should be 12 intra-molecular disufide bonds, and four inter-molecular disulfide bonds.  The cysteine pairings in the figure are those expected for IgG1 antibodies.  ABP 215 is glycosylated, on the 2nd constant domain of the heavy chain (N303).",
      "heavychain": "EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": "DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC",
      "heavychain_image": "hc_abp215.png",
      "lightchain_image": "lc_abp215.png",
      "sequence_legend": "legend_abp494.png",
      "formulation_text": "51 mM sodium phosphate, 60 mg/mL α,α-trehalose dihydrate, 0.04% (w/v) polysorbate 20, pH 6.2",
      "target_text": "ABP 215 binds to vascular endothelial growth factor A (VEGF-A) inhibiting the interaction of VEGF-A with its receptors, VEGFR-1 and VEGFR-2. ABP 215 inhibits establishment of the new blood vessels necessary for the maintenance and growth of solid tumors.",
      "therapeuticindications_text": "Oncology: glioblastoma (GBM), Metastatic Colorectal Cancer , Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Renal Cell Carcinoma.",
      "milestones_text": [
            "Tox DS production completed 6/7/2011",
            "IND Filing 4/30/2012",
            "EOPI  meeting Q2 2013",
            "PHIII studies Q4 2013-Q1 2016",
            "BLA submission Q3 -2016"
      ],
      "issueschallenges_text": "",
      "bioassay": ["MET-002786"],
      "idelisa": "MET-002795",
      "chargeassay": "MET-002791",
      "sec": "MET-002818",
      "rcesds": "MET-002817",
      "titer": "MET-000195",
      "chopelisa": "MET-002820 ",
      "proaelisa": "MET-002821",
      "bioassayLink": ["http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d818152b9/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d816c64f0"],
      "idelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82b56749/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d8172c7a9",
      "chargeassayLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d821c1627/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d816f1afa",
      "secLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d826ea265/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d8179b9ee",
      "rcesdsLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d81a10289/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d81799519",
      "titerLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d81177033/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d80114fbe",
      "chopelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d817b7aaf/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d817a40a9",
      "proaelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d817a41bb/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d817a41bb",
      "process_lead": "Suresh Vunnum",
      "analytical_lead": "Alla Polozova",
      "formulation_lead": "Shab Molloy",
      "upstream_lead": "Dan Leiske/Neil Kitchen",
      "downstream_lead": "Ron Gillespie",
      "fileLink": "",
      "allfilters": "tile active monolonal igg1 kappalc biosimilar oncology"
    },   
    {
      "molecule_name": "ABP 494",
      "status_text": "Active in Development",
      "stage_text": "Biosimilar",
      "tile_icon": "igg1kappa.svg",
      "alternate_names": "Cetucimab (Erbitux®) biosimilar",
      "molecule_illustration": "abp494.png",
      "pstformed": "2/2013",
      "pstraw": "201302",
      "class1": "IgG1",
      "class2": "Kappa LC",
      "modality": "Monoclonal Antibody",
      "extinctioncoeff": "1.4",
      "peptidemw": "145,563",
      "pi": "8.4",
      "summary_text": "",
      "heavychain": "QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": "DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC",
      "heavychain_image": "hc_abp494.png",
      "lightchain_image": "lc_abp494.png",
      "sequence_legend": "legend_abp494.png",
      "formulation_text": "10 mM citrate, 0.1 M sodium chloride,  0.1 M glycine, 0.01% polysorbate 80, pH 5.5",
      "target_text": "Against human EGFR.",
      "therapeuticindications_text": "Oncology – squamous cell carcinoma, metastic colorectal cancer",
      "milestones_text": "",
      "issueschallenges_text": "",
      "bioassay": ["MET-003542"],
      "idelisa": "",
      "chargeassay": "TP-001840",
      "sec": "TP-001097",
      "rcesds": "TP-001842",
      "titer": "MET-003271",
      "chopelisa": "MET-000180",
      "proaelisa": "MET-001363",
      "bioassayLink": ["http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82500dce/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d82500133"],
      "idelisaLink": "",
      "chargeassayLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82c75a0c/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d82c758f6",
      "secLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d818dc9e7/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d8147e16b",
      "rcesdsLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82c75a33/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d82c75d51",
      "titerLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d821f2498/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d81ec636d",
      "chopelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8219023e/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d80114d79",
      "proaelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8256d09f/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d801675bf",
      "process_lead": "Diana Woehle",
      "analytical_lead": "Tian Wang",
      "formulation_lead": "Arnold McAuley",
      "upstream_lead": "Sean Cole",
      "downstream_lead": "Xiaoyang Zhao",
      "fileLink": "",
      "allfilters": "tile monolonal active igg1 kappalc biosimilar oncology"
    },
    {
      "molecule_name": "ABP 501",
      "status_text": "Active in Development",
      "stage_text": "Biosimilar",
      "tile_icon": "igg1kappa.svg",
      "alternate_names": "Anti-TNFα Antibody, adalimumab (Humira®) biosimilar",
      "molecule_illustration": "abp501.png",
      "pstformed": "6/2009",
      "pstraw": "200906",
      "class1": "IgG1",
      "class2": "Kappa LC",
      "modality": "Monoclonal Antibody",
      "extinctioncoeff": "1.4",
      "peptidemw": "145,190",
      "pi": "8.7",
      "summary_text": "Based on the putative structure of IgG1 antibodies, the protein is composed of two heavy chains, and two light chains.  There should be 12 intra-molecular disufide bonds, and four inter-molecular disulfide bonds.  The cysteine pairings in the figure are those expected for IgG1 antibodies.  ABP 501 is glycosylated, on the 2nd constant domain of the heavy chain (N301).",
      "heavychain": "EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": "DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC",
      "heavychain_image": "hc_abp501.png",
      "lightchain_image": "lc_abp501.png",
      "sequence_legend": "legend_abp494.png",
      "formulation_text": "10 mM sodium acetate, 9% (w/v) sucrose, 0.10% (w/v) polysorbate 80, pH 5.2",
      "target_text": "ABP 501 is targeted against Tumor necrosis factor alpha (TNFα), and inhibits the binding of TNFα to the cell surface TNF receptors.",
      "therapeuticindications_text": "Inflammation: Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn’s Disease and Plaque Psoriasis.",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": ["MET-002819"],
      "idelisa": "MET-002840",
      "chargeassay": "MET-002843",
      "sec": "MET-002842",
      "rcesds": "MET-002841",
      "titer": "MET-000195",
      "chopelisa": "MET-002837",
      "proaelisa": "MET-002838",
      "bioassayLink": ["http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82052a1a/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d8179c2d2"],
      "idelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d81837c76/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d817c7423",
      "chargeassayLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8181670a/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d817c752a",
      "secLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d81865bce/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d817c74cc",
      "rcesdsLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8186174d/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d817c74c9",
      "titerLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d81177033/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d80114fbe",
      "chopelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8219290a/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d817c7303",
      "proaelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8256d514/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d817c73c5",
      "process_lead": "Jennifer Liu",
      "analytical_lead": "Tamer Eris",
      "formulation_lead": "Jeff Abel",
      "upstream_lead": "Junfen Ma",
      "downstream_lead": "Swapnil Bhargava",
      "fileLink": "",
      "allfilters": "tile monoclonal igg1 active kappalc biosimilar rheumatoidarthritis psoriaticarthritis psoriasis chronsdisease"
    },
    {
      "molecule_name": "ABP 710",
      "status_text": "Active in Development",
      "stage_text": "Biosimilar",
      "tile_icon": "igg1kappa.svg",
      "alternate_names": "infliximab (Remicade®) biosimilar",
      "molecule_illustration": "abp710.png",
      "pstformed": "",
      "pstraw": "0",
      "class1": "IgG1",
      "class2": "Kappa LC",
      "modality": "Monoclonal Antibody",
      "extinctioncoeff": "1.4",
      "peptidemw": "145,623",
      "pi": "7.5",
      "summary_text": "",
      "heavychain": "EVKLEESGGGLVQPGGSMKLSCVASGFIFSNHWMNWVRQSPEKGLEWVAEIRSKSINSATHYAESVKGRFTISRDDSKSAVYLQMTDLRTEDTGVYYCSRNYYGSTYDYWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": "DILLTQSPAILSVSPGERVSFSCRASQFVGSSIHWYQQRTNGSPRLLIKYASESMSGIPSRFSGSGSGTDFTLSINTVESEDIADYYCQQSHSWPFTFGSGTNLEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC",
      "heavychain_image": "hc_abp710.png",
      "lightchain_image": "lc_abp710.png",
      "sequence_legend": "legend_abp710.png",
      "formulation_text": "10 mM sodium phosphate, 10% (w/v) sucrose, 0.01%poolysorbate 80, pH 7.2",
      "target_text": "TNF alpha",
      "therapeuticindications_text": "Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, Irritable Bowel Disease.",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": ["MET-003603"],
      "idelisa": "MET-003573",
      "chargeassay": "MET-003569",
      "sec": "MET-003566",
      "rcesds": "MET-003567",
      "titer": "MET-003565",
      "chopelisa": "MET-003576",
      "proaelisa": "MET-003575",
      "bioassayLink": ["http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d828f0c84/versionLabel/1.0/format/pdf/chronicleId/09014b2d827ab77c"],
      "idelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8291898c/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d825af3c8",
      "chargeassayLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8297993f/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d825af175",
      "secLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82931f56/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d825aef7d",
      "rcesdsLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82a195eb/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d825af008",
      "titerLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82953603/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d825aee5c",
      "chopelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82953935/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d825af4a1",
      "proaelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82959ea2/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d825af49c",
      "process_lead": "Lisa Connell-Crowley",
      "analytical_lead": "Danielle Pace",
      "formulation_lead": "Duke Phan",
      "upstream_lead": "Dan Leiske",
      "downstream_lead": "Pete Hinckley",
      "fileLink": "",
      "allfilters": "tile active monoclonal igg1 kappalc biosimilar rheumatoidarthritis psoriaticarthritis psoriasis irritableboweldisease"
    },
    {
      "molecule_name": "ABP 798",
      "status_text": "Active in Development",
      "stage_text": "Biosimilar",
      "tile_icon": "igg1kappa.svg",
      "alternate_names": "rituximab (Rituxan® and MabThera®) biosimilar",
      "molecule_illustration": "abp798.png",
      "pstformed": "6/2014",
      "pstraw": "201406",
      "class1": "IgG1",
      "class2": "Kappa LC",
      "modality": "Monoclonal Antibody",
      "extinctioncoeff": "1.7",
      "peptidemw": "144,187",
      "pi": "9.5",
      "summary_text": "",
      "heavychain": "QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": "QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC",
      "sequence_legend": "legend_abp494.png",
      "heavychain_image": "hc_abp798.png",
      "lightchain_image": "lc_abp798.png",
      "formulation_text": "154 mM sodium chloride, 25 mM sodium citrate dihydrate, with 0.07% polysorbate 80, pH 6.5",
      "target_text": "ABP 798 is a recombinant mouse/human chimeric IgG1 monoclonal antibody that specifically binds to the CD20 antigen expressed on B-cells and promotes Fc-mediated target cell killing.",
      "therapeuticindications_text": "Oncology – non-Hodgkins Lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": ["MET-003280"],
      "idelisa": "MET-003417",
      "chargeassay": "MET-003372",
      "sec": "MET-003368",
      "rcesds": "MET-003426",
      "titer": "MET-003532",
      "chopelisa": "MET-003517",
      "proaelisa": "MET-003519",
      "bioassayLink": ["http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d826fab96/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d81f3d116"],
      "idelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d827197c3/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d823059f9",
      "chargeassayLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8269dfb7/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d82215b55",
      "secLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8269dc11/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d822083fa",
      "rcesdsLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d827adaef/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d82339856",
      "titerLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82680fa7/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d824e1218",
      "chopelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82673386/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d82472019",
      "proaelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8267333f/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d82476c1d",
      "process_lead": "Junfen Ma",
      "analytical_lead": "Bob Duff",
      "formulation_lead": "Shawn Cao",
      "upstream_lead": "Li Zhang",
      "downstream_lead": "Hai Hong",
      "fileLink": "",
      "allfilters": "tile monoclonal igg1 biosimilar active kappalc oncology rheumatoidarthritis"
    },
    {
      "molecule_name": "ABP 895",
      "status_text": "Active in Development",
      "stage_text": "Biosimilar",
      "tile_icon": "igg4kappa.svg",
      "alternate_names": "natalizumab (Tysabri®) biosimilar",
      "molecule_illustration": "abp895.png",
      "pstformed": "4/2014",
      "pstraw": "201404",
      "class1": "IgG4",
      "class2": "Kappa LC",
      "modality": "Monoclonal Antibody",
      "extinctioncoeff": "1.5",
      "peptidemw": "144,922",
      "pi": "7.7",
      "summary_text": "",
      "heavychain": "QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTYIHWVRQAPGQRLEWMGRIDPANGYTKYDPKFQGRVTITADTSASTAYMELSSLRSEDTAVYYCAREGYYGNYGVYAMDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK",
      "lightchain": "DIQMTQSPSSLSASVGDRVTITCKTSQDINKYMAWYQQTPGKAPRLLIHYTSALQPGIPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDNLWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC",
      "sequence_legend": "legend_abp895.png",
      "heavychain_image": "hc_abp895.png",
      "lightchain_image": "lc_abp895.png",
      "formulation_text": "10mM sodium acetate, 9% sucrose, 0.01% polysorbate 80, pH5.2",
      "target_text": "",
      "therapeuticindications_text": "Inflammation - Chron's Disease and Multiple Sclerosis",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": [""],
      "idelisa": "",
      "chargeassay": "",
      "sec": "",
      "rcesds": "",
      "titer": "",
      "chopelisa": "",
      "proaelisa": "",
      "bioassayLink": [""],
      "idelisaLink": "",
      "chargeassayLink": "",
      "secLink": "",
      "rcesdsLink": "",
      "titerLink": "",
      "chopelisaLink": "",
      "proaelisaLink": "",
      "process_lead": "Brad Dell",
      "analytical_lead": "Zach Yates",
      "formulation_lead": "Nate Ball",
      "upstream_lead": "Neil Kitchen",
      "downstream_lead": "John Skonier",
      "fileLink": "",
      "allfilters": "tile monoclonal active igg4 biosimilar kappalc cronsdisease multiplesclerosis"
    },
    {
      "molecule_name": "ABP 959",
      "status_text": "Active in Development",
      "stage_text": "Biosimilar",
      "tile_icon": "igg2igg4kappa.svg",
      "alternate_names": "eculizumab (Soliris ®) biosimilar",
      "molecule_illustration": "abp959.png",
      "pstformed": "4/2014",
      "pstraw": "201404",
      "class1": "IgG4",
      "class2": "IgG2",
      "class3": "Kappa LC",
      "modality": "Monoclonal Antibody",
      "extinctioncoeff": "1.5",
      "peptidemw": "147,870",
      "pi": "6.3",
      "summary_text": "",
      "heavychain": "QVQLVQSGAEVKKPGASVKVSCKASGYIFSNYWIQWVRQAPGQGLEWMGEILPGSGSTEYTENFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYFFGSSPNWYFDVWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK",
      "lightchain": "DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKPGKAPKLLIYGATNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNVLNTPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC",
      "sequence_legend": "legend_abp959.png",
      "heavychain_image": "hc_abp959.png",
      "lightchain_image": "lc_abp959.png",
      "formulation_text": "sodium phosphate, pH7 with polysorbate 80",
      "target_text": "ABP 959 inhibits the C5 Convertase Enzyme",
      "therapeuticindications_text": "Paroxysmal nocturnal hemoglobinuria, atypical haemolytic uraemic syndrome",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": [""],
      "idelisa": "",
      "chargeassay": "",
      "sec": "",
      "rcesds": "",
      "titer": "",
      "chopelisa": "",
      "proaelisa": "",
      "bioassayLink": [""],
      "idelisaLink": "",
      "chargeassayLink": "",
      "secLink": "",
      "rcesdsLink": "",
      "titerLink": "",
      "chopelisaLink": "",
      "proaelisaLink": "",
      "process_lead": "Tamer Eris",
      "analytical_lead": "Bob Duff",
      "formulation_lead": "Jun Zhang",
      "upstream_lead": "Jack Huang",
      "downstream_lead": "Neil Soice",
      "fileLink": "",
      "allfilters": "tile active monoclonal igg4 igg2 biosimilar kappalc paroxysmalnocturnalhemoglobinuria atypicalhaemolyticuraemicsyndrome"
    },
    {
      "molecule_name": "ABP 980",
      "status_text": "Active in Development",
      "stage_text": "Biosimilar",
      "tile_icon": "igg1kappa.svg",
      "alternate_names": "trastuzumab (Herceptin®) biosimilar",
      "molecule_illustration": "abp980.png",
      "pstformed": "",
      "pstraw": "0",
      "class1": "IgG1",
      "class2": "Kappa LC",
      "modality": "Monoclonal Antibody",
      "extinctioncoeff": "1.5",
      "peptidemw": "145,422",
      "pi": "8.8",
      "summary_text": "",
      "heavychain": "EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": "DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC",
      "sequence_legend": "legend_abp980.png",
      "heavychain_image": "hc_abp980.png",
      "lightchain_image": "lc_abp980.png",
      "formulation_text": "50 mM trehalose, 4.2 mM histidine, 0.08% polysorbate 20, pH 6.0",
      "target_text": "Antibody directed against human epidermal growth factor receptor 2 (HER 2).  The antibody binds to HER 2 that is present in cancers over-expressing this receptor, and results in a reduction in proliferation.  Activity is also mediated through antibody dependent cell-mediated cytotoxicity.",
      "therapeuticindications_text": "Oncology – Breast and Gastric Cancer",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": ["MET-003337"],
      "idelisa": "MET-003266",
      "chargeassay": "MET-003294",
      "sec": "MET-003335",
      "rcesds": "MET-003313",
      "titer": "MET-003339",
      "chopelisa": "MET-003341",
      "proaelisa": "MET-003340",
      "bioassayLink": ["http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82ecf03d/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d82173037"],
      "idelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82b561c8/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d81df3cf1",
      "chargeassayLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8273533e/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d81fc0ce0",
      "secLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d826bc09a/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d82142c81",
      "rcesdsLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d823928a1/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d820acd64",
      "titerLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d825b5472/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d821731fb",
      "chopelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82515fe9/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d8217330c",
      "proaelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82515d91/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d82173264",
      "process_lead": "Aaron Pilling",
      "analytical_lead": "Alla Polozova",
      "formulation_lead": "Shon Crampton",
      "upstream_lead": "Kurt Kunas",
      "downstream_lead": "Russell Van Buskirk",
      "fileLink": "",
      "allfilters": "tile monoclonal active igg1 biosimilar kappalc oncology"
    },
    {
      "molecule_name": "AMG 102",
      "status_text": "Inactive",
      "stage_text": "CPD",
      "tile_icon": "igg2kappa.svg",
      "alternate_names": "Rilotumumab, Anti-HGF Antibody",
      "molecule_illustration": "amg102.png",
      "pstformed": "9/2002",
      "pstraw": "200209",
      "class1": "IgG2",
      "class2": "Kappa LC",
      "modality": "Monoclonal Antibody",
      "extinctioncoeff": "1.6",
      "peptidemw": "145,207",
      "pi": "8.1",
      "summary_text": "The protein is composed of two heavy chains (HC), and two light chains (LC).  There are 12 intra-chain disulfide bonds, and six inter-chain disulfide bonds.  AMG 102 has one glycosylation site located on the 2nd constant domain of the heavy chain (N296 glycan).",
      "heavychain": "QVQLQESGPGLVKPSETLSLTCTVSGGSISIYYWSWIRQPPGKGLEWIGYVYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTAVYYCARGGYDFWSGYFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": "EIVMTQSPATLSVSPGERATLSCRASQSVDSNLAWYRQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYINWPPITFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC",
      "sequence_legend": "%$*#",
      "heavychain_image": "hc_amg102.png",
      "lightchain_image": "lc_amg102.png",
      "formulation_text": "10mM Sodium Acetate, 9 % sucrose, 0.004% polysorbate 20, pH of 5.4, 30mg/mL",
      "target_text": "HGF signals through its receptor, c-met, to stimulate cell proliferation.",
      "therapeuticindications_text": "Oncology: colon, lung, prostate, breast and other cancers",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": ["A01628"],
      "idelisa": "MET-001853",
      "chargeassay": "A01612",
      "sec": "A01613",
      "rcesds": "A01635",
      "titer": "A01611",
      "chopelisa": "A01630",
      "proaelisa": "A01633",
      "bioassayLink": [""],
      "idelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82b41f3c/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d8046d849",
      "chargeassayLink": "",
      "secLink": "",
      "rcesdsLink": "",
      "titerLink": "",
      "chopelisaLink": "",
      "proaelisaLink": "",
      "process_lead": "Brad Dell",
      "analytical_lead": "Yuling Zhang",
      "formulation_lead": "Bill Callahan",
      "upstream_lead": "Brad Dell",
      "downstream_lead": "Benj Guzman",
      "fileLink": "",
      "allfilters": "tile monoclonal igg2 kappalc cpd inactive oncology"
    },
    {
      "molecule_name": "AMG 103",
      "status_text": "Marketed Product",
      "stage_text": "Marketed Product",
      "tile_icon": "bitecd3.png",
      "alternate_names": "Blinatumomab, BLINCYTO",
      "molecule_illustration": "amg103.png",
      "pstformed": "",
      "pstraw": "0",
      "class1": "CD3",
      "class2": "",
      "modality": "BiTe",
      "extinctioncoeff": "2.2",
      "peptidemw": "54,086",
      "pi": "7.7",
      "summary_text": "AMG 103 is a novel, single-chain, bi-specific antibody derivative of the bi-specific T-cell engager (BiTE®) class, containing CD-19 and CD-3 functionality.  The single chain Fv regions (with the respective heavy chain and light chain components linked via a poly-glycine linker) are linked via a poly-glycine linker to form a single polypeptide of 504 amino acids.  There are 4 intramolecular disulfide bonds consistent with the expected intramolecular disulfides from the residual IgG framework.",
      "heavychain": "DIQLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLNWYQQIPGQPPKLLIYDASNLVSGIPPRFSGSGSGTDFTLNIHPVEKVDAATYHCQQSTEDPWTFGGGTKLEIKGGGGSGGGGSGGGGSQVQLQQSGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIWPGDGDTNYNGKFKGKATLTADESSSTAYMQLSSLASEDSAVYFCARRETTTVGRYYYAMDYWGQGTTVTVSSGGGGSDIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKHHHHHH",
      "lightchain": "%$*#",
      "heavychain_image": "hc_amg103.png",
      "lightchain_image": "%$*#",
      "sequence_legend": "legend_amg103.png",
      "formulation_text": "25 mM citrate, 200 mM lysine, 15% trehalose, 0.1% polysorbate 80, pH 7.0",
      "target_text": "AMG 103 is a bispecific antibody with one functional region binding the CD3e subunit of the T-cell receptor complex (TCRC) and the other functional region binding CD19 specifically expressed on B cells.  By binding both T-cells and B-cells, AMG 103 effectively recruits the cancer cell and killer cell, inducing killer cell proliferation through binding the CD3e, leading to lysis of the B-cell.",
      "therapeuticindications_text": "Oncology: acute lymphoblastic leukemia (ALL)",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": ["MET-003375"],
      "idelisa": "MET-003446",
      "chargeassay": "MET-003332",
      "sec": "TP-001410",
      "rcesds": "UKSL-7953",
      "titer": "MET-003318",
      "chopelisa": "MET-003503",
      "proaelisa": "",
      "bioassayLink": ["http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82c908bb/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d8222377d"],
      "idelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82ecd905/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d823748c6",
      "chargeassayLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82ea0b10/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d82123691",
      "secLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8257c596/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d81eae0cb",
      "rcesdsLink": "",
      "titerLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82e63310/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d820d03dd",
      "chopelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d829cdc86/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d82444a3f",
      "proaelisaLink": "",
      "process_lead": "",
      "analytical_lead": "Brad Prater",
      "formulation_lead": "",
      "upstream_lead": "",
      "downstream_lead": "",
      "fileLink": "",
      "allfilters": "tile cd3 bite marketedproduct oncology"
    },
    {
      "molecule_name": "AMG 132",
      "status_text": "Inactive",
      "stage_text": "FIH",
      "tile_icon": "igg1kappa.svg",
      "alternate_names": "Anti-amyloid Antibody",
      "molecule_illustration": "amg132.png",
      "pstformed": "10/2006",
      "pstraw": "200610",
      "class1": "IgG1",
      "class2": "Kappa LC",
      "modality": "Monoclonal Antibody",
      "extinctioncoeff": "1.2",
      "peptidemw": "146,824",
      "pi": "9.1",
      "summary_text": "Based on the putative structure of IgG1 antibodies, the protein is likely composed of two heavy chains, and two light chains.  There should be 12 intra-molecular disufide bonds, and four inter-molecular disulfide bonds.  The cysteine pairings in the figure are those expected for IgG1 antibodies.  AMG 132 is glycosylated, presumably on the 2nd constant domain of the heavy chain (N301).",
      "heavychain": "QVTLKESGPVLLKPTETLTLTCTVSGFSLSNARMGVSWIRQPPGKALEWLAHIFSNDEKSYITSLKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARIPLRSPGAFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": "DIVMTQTPLSSPVTLGQPASISCRSSQSLVHSDGNTYLNWLQQRPGQPPRLLIYKISNRFSGVPDRFTGSGAGTDFTLKISRVEAEDVGVYTCMQVTQFPLTFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC",
      "heavychain_image": "hc_amg132.png",
      "lightchain_image": "lc_amg132.png",
      "sequence_legend": "%$*#",
      "formulation_text": "10mM sodium acetate, 5% sorbitol, 0.004% polysorbate 20, pH 5.0",
      "target_text": "AMG 132 targets amyloid beta peptide (Ab) and acts either by microglial cell dependent phagocytosis of amyloid deposts, capture of soluble Ab or direct antibody disruption of amyloid deposits. ",
      "therapeuticindications_text": "Alzheimer’s Disease",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": [""],
      "idelisa": "",
      "chargeassay": "",
      "sec": "",
      "rcesds": "",
      "titer": "",
      "chopelisa": "",
      "proaelisa": "",
      "bioassayLink": [""],
      "idelisaLink": "",
      "chargeassayLink": "",
      "secLink": "",
      "rcesdsLink": "",
      "titerLink": "",
      "chopelisaLink": "",
      "proaelisaLink": "",
      "process_lead": "",
      "analytical_lead": "Randal Bass",
      "formulation_lead": "",
      "upstream_lead": "",
      "downstream_lead": "",
      "fileLink": "",
      "allfilters": "tile monoclonal igg1 kappalc fih inactive alzheimers"
    },
    {
      "molecule_name": "AMG 145",
      "status_text": "Active in Development",
      "stage_text": "Post-CPD",
      "tile_icon": "igg2lambda.svg",
      "alternate_names": "Evolocumab, anti-PCSK9",
      "molecule_illustration": "amg145.png",
      "pstformed": "12/2007",
      "pstraw": "200712",
      "class1": "IgG2",
      "class2": "Lambda LC",
      "modality": "Monoclonal Antibody",
      "extinctioncoeff": "1.5",
      "peptidemw": "143,775",
      "pi": "8.1",
      "summary_text": "AMG 145 (anti-PCSK9) is a fully-human monoclonal antibody produced in CHO cells.  It is a heterotetramer consisting of two heavy chains of the IgG2 subclass and two light chains of the lamda subclass.  There are 12 intramolecular disulfide bonds, and six intermolecular disulfide bonds.  AMG 145 has a single glycosylation site located on the 2nd constant domain of each heavy chain (N291).",
      "heavychain": "EVQLVQSGAEVKKPGASVKVSCKASGYTLTSYGISWVRQAPGQGLEWMGWVSFYNGNTNYAQKLQGRGTMTTDPSTSTAYMELRSLRSDDTAVYYCARGYGMDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": "ESALTQPASVSGSPGQSITISCTGTSSDVGGYNSVSWYQQHPGKAPKLMIYEVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCNSYTSTSMVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS",
      "heavychain_image": "hc_amg145.png",
      "lightchain_image": "lc_amg145.png",
      "sequence_legend": "legend_amg162.png",
      "formulation_text": "20 mM sodium acetate, 230 mM proline, 0.010% (w/v) polysorbate 80, pH 5.0",
      "target_text": "Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease involved in degradation of the low density lipoprotein receptor (LDLR). LDLR is a key regulator of plasma LDL-cholesterol (LDL-C) levels. Blocking PCSK9 inhibits intracellular degradation of LDLR thereby accelerates clearance of plasma LDL.",
      "therapeuticindications_text": "Coronary Heart Disease",
      "milestones_text": [            
            "FIH PST formed Dec 2007",
            " IND filed in US, May 2009",
            " CPD Gate Oct 2010",
            " IND amendment for Process 1 filed May 2011",
            " IND amendment for Process 2 filed Dec 2012",
            " ARI engineering and pivotal runs (15 kL) competed"
      ],
      "issueschallenges_text": "",
      "bioassay": ["MET-003305"],
      "idelisa": "MET-002276",
      "chargeassay": "MET-002935",
      "sec": "MET-002824",
      "rcesds": "MET-002794",
      "titer": "MET-000610",
      "chopelisa": "MET-002835",
      "proaelisa": "MET-002850",
      "bioassayLink": ["http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8275ca1e/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d82023fbe"],
      "idelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8290990c/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d805806b5",
      "chargeassayLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82ede846/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d819e4b8e",
      "secLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d828e410c/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d817adf0f",
      "rcesdsLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82bdcc3a/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d8172af91",
      "titerLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82ebd677/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d801161f7",
      "chopelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8249c8f4/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d817b882d",
      "proaelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d825a4548/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d817d7122",
      "process_lead": "Jette Wypych",
      "analytical_lead": "Xin Zhang",
      "formulation_lead": "Tim Osslund",
      "upstream_lead": "",
      "downstream_lead": "",
      "fileLink": "",
      "allfilters": "tile monoclonal igg2 lambdalc postcpd active coronaryheartdisease"
    },
    {
      "molecule_name": "AMG 147",
      "status_text": "Active in Development",
      "stage_text": "Reagent Approach",
      "tile_icon": "igg2kappalambda.svg",
      "alternate_names": "FM-2",
      "molecule_illustration": "amg147.png",
      "pstformed": "12/2013",
      "pstraw": "201312",
      "class1": "IgG2",
      "class2": "Lambda LC",
      "class3": "Kappa LC",
      "modality": "Bispecific",
      "extinctioncoeff": "1.5",
      "peptidemw": "144,241",
      "pi": "7.2",
      "summary_text": "",
      "heavychain": "#1 QVQLVESGGGVVQPGRSLRLSCAASGFTFSRYDMHWVRQAPGKGLEWVAIIFYDGSNKYYADPVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATLAAAFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLKSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYDTTPPMLDSDGSFFLYSDLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK #2 EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMHWVRQAPGQGLEWMGEINPNSGGAGYNQKFKGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARLGYDDIYDDWYFDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLESVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSRKEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLKSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": " #1 SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSEIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTRLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAAESYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS #2 DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLLSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGDTLPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLKSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC",
      "heavychain_image": "hc_amg147.png",
      "lightchain_image": "lc_amg147.png",
      "sequence_legend": "legend_amg147.png",
      "formulation_text": "10 mM sodium acetate, 9.0% (w/v) sucrose, 0.01% (w/v) polysorbate 80, pH 5.2",
      "target_text": "AMG 147 is a ispecific antagonist of Sclerostin and DKK1. Sclerostin and DKK1 are known inhibitors of Wnt signaling, which is responsible for bone growth and remodeling. FM-2 is designed to neutralize both sclerostin and DKK1 to promote bone anabolism and fracture healing.",
      "therapeuticindications_text": "Fracture Healing",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": ["MET-003696", "MET-003697"],
      "idelisa": "MET-003734",
      "chargeassay": "MET-003733",
      "sec": "MET-002933",
      "rcesds": "MET-003745",
      "titer": "MET-003732",
      "chopelisa": "MET-000180",
      "proaelisa": "MET-003735 ",
      "bioassayLink": ["http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82e04443/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d82be7631", "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82e0e52e/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d82be7638"],
      "idelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82e0e69d/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d82cac391",
      "chargeassayLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82e86251/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d82cac35c",
      "secLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d821e5b9a/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d819c2319",
      "rcesdsLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82dc7ba2/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d82d1d585",
      "titerLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82e234f3/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d82cac2db",
      "chopelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8219023e/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d80114d79",
      "proaelisaLink": "",
      "process_lead": "Ramsey Saleem",
      "analytical_lead": "Ramsey Saleem",
      "formulation_lead": "Shon Crampton",
      "upstream_lead": "Brad Dell",
      "downstream_lead": "Anna Senczuk",
      "fileLink": "",
      "allfilters": "tile bispecific igg2 lambdalc kappalc reagentapproach active fracturehealing"
    },
    {
      "molecule_name": "AMG 157",
      "status_text": "Active in Development",
      "stage_text": "CPD",
      "tile_icon": "igg2lambda.svg",
      "alternate_names": "Anti-TSLP",
      "molecule_illustration": "amg157.png",
      "pstformed": "10/2006",
      "pstraw": "200610",
      "class1": "IgG2",
      "class2": "Lambda LC",
      "modality": "Monoclonal Antibody",
      "extinctioncoeff": "1.7",
      "peptidemw": "144,591",
      "pi": "7.2",
      "summary_text": "The protein is composed of two heavy chains and two light chains.  There are 12 intra-heavy and intra-light chains disulfide bonds, four inter-heavy chains, and two inter-heavy and light chains disulfide bonds.  AMG 157 has one N-linked glycosylation site located in the CH2 domain of the heavy chain (N298 glycan). The N-terminus Glutamine is ~100 % cyclized to pyroglutamic acid.  The C-terminus Lysine is ~100 % clipped off during cell cultural process.",
      "heavychain": "QMQLVESGGGVVQPGRSLRLSCAASGFTFRTYGMHWVRQAPGKGLEWVAVIWYDGSNKHYADSVKGRFTITRDNSKNTLNLQMNSLRAEDTAVYYCARAPQWELVHEAFDIWGQGTMVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": "SYVLTQPPSVSVAPGQTARITCGGNNLGSKSVHWYQQKPGQAPVLVVYDDSDRPSWIPERFSGSNSGNTATLTISRGEAGDEADYYCQVWDSSSDHVVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS",
      "heavychain_image": "hc_amg157.png",
      "lightchain_image": "lc_amg157.png",
      "sequence_legend": "legend_amg157.png",
      "formulation_text": "10 mM sodium acetate, 9.0% sucrose, 0.004% Polysorbate 20, pH 5.2",
      "target_text": "AMG 157 is a fully human antagonistic antibody to Thymic Stromal Lymphopoeitin (TSLP). TSLP is an epithelial cell derived cytokine produced in response to pro-inflammatory stimuli. In atopic skin and asthmatic airways, TSLP promotes allergic inflammatory responses primarily through its activity on dendritic and mast cells.",
      "therapeuticindications_text": "Asthma",
      "milestones_text": [
            "Clone selection by April 30, 2007",
            "Assay transfer to PDF by June 20, 2007",
            "Assay transfer to QLA by Dec, 2007",
            "CPD started May 2013"
      ],
      "issueschallenges_text": "",
      "bioassay": [""],
      "idelisa": "",
      "chargeassay": "",
      "sec": "",
      "rcesds": "",
      "titer": "",
      "chopelisa": "",
      "proaelisa": "",
      "bioassayLink": [""],
      "idelisaLink": "",
      "chargeassayLink": "",
      "secLink": "",
      "rcesdsLink": "",
      "titerLink": "",
      "chopelisaLink": "",
      "proaelisaLink": "",
      "process_lead": "Eva Gefroh",
      "analytical_lead": "Patrick Finerty",
      "formulation_lead": "Joon Huh",
      "upstream_lead": "Brent Grisim",
      "downstream_lead": "Sean MacNeil",
      "fileLink": "",
      "allfilters": "tile monoclonal igg2 lambdalc cpd active asthma"
    },
    {
      "molecule_name": "AMG 162",
      "status_text": "Marketed Product",
      "stage_text": "Marketed Product",
      "tile_icon": "igg2kappa.svg",
      "alternate_names": "Denosumab, Prolia, Xgeva, Abgenix 1-6 CHO OPG, Ligand mAb IgG2",
      "molecule_illustration": "amg162.png",
      "pstformed": "6/2003",
      "pstraw": "200306",
      "class1": "IgG2",
      "class2": "Kappa LC",
      "modality": "Monoclonal Antibody",
      "extinctioncoeff": "1.4",
      "peptidemw": "144,627",
      "pi": "8.8",
      "summary_text": "AMG 162 is a full-length, fully-human monoclonal antibody produced in CHO cells.  It is a heterotetramer consisting of two heavy chains of the IgG2 subclass and two light chains of the kappa subclass.  There are 12 intramolecular disulfide bonds, and six intermolecular disulfide bonds.  AMG 162 has a single glycosylation site located on the 2nd constant domain of each heavy chain (N298 glycan).",
      "heavychain": "EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGITGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPGTTVIMSWFDPWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": "EIVLTQSPGTLSLSPGERATLSCRASQSVRGRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVFYCQQYGSSPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC",
      "heavychain_image": "hc_amg162.png",
      "lightchain_image": "lc_amg162.png",
      "sequence_legend": "legend_amg162.png",
      "formulation_text": "10mM sodium acetate, 5% sorbitol, pH 5.2",
      "target_text": "AMG 162 targets Receptor Activator of Nuclear Factor kappa B Ligand (RANK-L).  RANK-L is produced by osteoblasts in response to bone resorptive agents, and interacts with its receptor to promote differentiation, increase osteoclast numbers and increase bone resorption. AMG 162 prevents RANK-L binding to RANK, preventing the undesired loss of bone.",
      "therapeuticindications_text": "Osteoporosis in postmenopausal women and Hypercalcemia of malignancy and bone metastasis in oncology.",
      "milestones_text": [
            "IND filed in US, 5/2001. First patient dosd in 6/2001.",
            "CTX filed in Europe, 6/2001. First patient dosed in 9/2001.",
            "IND amendment submitted with the change in process Q3 2002.",
            "Briefing document with changes from FIH (CP1) process to phase III (CP2) process submitted in US 3/2004. Additional information submitted 7/2004.",
            "IND amendment submitted with the CP2 process and data from 3 non-GMP and 2 GMP runs, 4/2004."
      ],
      "issueschallenges_text": "AMG 162 is currently manufactured at Amgen’s clinical production facility in B-23, Thousand Oaks, California, in order to supply the phase III clinical trials. The product will be manufactured for commercial launch at Amgen’s LakeCentre facility product comparability will be demonstrated between material produced at 2,000 liter scale in Thousand Oaks and material produced at 15,000 liter scale at LakeCentre. Analytical methods will be validated prior to the conformance (validation) process runs, currently scheduled to start during Q1-2006. Long range plans include switching from current cell line (AM-1/D host CHO cell line) to a higher producing amplified cell line (CS-9 host cell line). The AMG 162 produced from second generation cell line will have to be comparable to CP2 derived material while the cell culture production reaches minimally product titers of 3 g per liter (current cell line produces about 0.95 g of AMG 162 per liter). The established timeline has conformance runs scheduled in 2008 for the process to be developed for the production of AMG 162 from the CS-9 derived cell line. The development work for the second generation process is currently taking place at Amgen’s facility at the Helix in Seattle, Washington. The BLA for AMG 162 is scheduled for submission in 11/2007 with subsequent product launch 9/2008.",
      "bioassay": ["MET-001146"],
      "idelisa": "MET-000614",
      "chargeassay": "MET-001098",
      "sec": "MET-001208",
      "rcesds": "MET-000092",
      "titer": "MET-000715",
      "chopelisa": "MET-000108",
      "proaelisa": "MET-000636",
      "bioassayLink": ["http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d81a42cea/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d801187cd"],
      "idelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d812b11bb/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d801162a4",
      "chargeassayLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d818319eb/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d801184d3",
      "secLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8179ecdf/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d801195b7",
      "rcesdsLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d811bf8b8/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d80114718",
      "titerLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d81976854/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d80116ba9",
      "chopelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d81448d37/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d8011480b",
      "proaelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8070aead/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d80116430",
      "process_lead": "Jim Weidner",
      "analytical_lead": "Wes Wang",
      "formulation_lead": "Ranjit Sarpal",
      "upstream_lead": "",
      "downstream_lead": "",
      "fileLink": "",
      "allfilters": "tile monoclonal igg2 kappalc marketedproduct oncology postmenopausalosteoporosis"
    },
    {
      "molecule_name": "AMG 181",
      "status_text": "Active in Development",
      "stage_text": "CPD",
      "tile_icon": "igg2kappa.svg",
      "alternate_names": "Anti-α4β7 mAb",
      "molecule_illustration": "amg181.png",
      "pstformed": "9/2008",
      "pstraw": "200809",
      "class1": "IgG2",
      "class2": "Kappa LC",
      "modality": "Monoclonal Antibody",
      "extinctioncoeff": "1.5",
      "peptidemw": "143,500",
      "pi": "6.8",
      "summary_text": "AMG 181 is composed of two heavy chains and two light chains.  Disulfide bonds are shown in thin lines.  There is a single glycosylation site located on the second constant domain of each heavy chain (N294).",
      "heavychain": "QVQLVQSGAEVKKPGASVKVSCKVSGYTLSDLSIHWVRQAPGKGLEWMGGFDPQDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLKSEDTAVYYCATGSSSSWFDPWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": "DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFANYYCQQANSFPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC",
      "heavychain_image": "hc_amg181.png",
      "lightchain_image": "lc_amg181.png",
      "sequence_legend": "legend_amg181.png",
      "formulation_text": "105 mg/mL in 19 mM sodium acetate, 240 mL L-proline, 0.1% (w/v) polysorbate 80, pH 5.0",
      "target_text": "a4b7 is highly expressed on a subset of gut homing lymphocytes and mediates gut homing through interaction with MAdCAM-1. MAdCAM-1 is selectively expressed in gut endothelium and is up regulated in inflammation. A fully human a4b7 heterodimer specific antibody 18A11 is selected as it is more potent than MLN-02, a clinically validated molecule that showed a loss of efficacy in an ulcerative colitis (UC) trial due to an increased HAHA response.",
      "therapeuticindications_text": "Inflammatory bowel disease (IBD)",
      "milestones_text": [
            "PST formation 10/2008",
            "Process Team formation 9/2008",
            "Non-GMP runs 1/2009 and 5/2009",
            "Tox Lot release 7/2009",
            "GMP Cell Culture/Harvest 8/2009",
            "GMP Purification 11/2009",
            "GMP Drug Product release 2/2010",
            "FIH Portal 3/2010",
            "IND Submission 4/2010",
            "Start FIH 6/2010"
      ],
      "issueschallenges_text": "",
      "processsummary_text": "The cell culture process is using chemically defined media in the 2000 L Reactor as depicted below. However the FIH process is using soy hydrolysate in the seed train up to and including the N-1, 300 L Reactor. Since a significant volume from the N-1 reactor is used to seed the 2000 L Reactor there are components of soy  hydrolysate in the process.",
      "bioassay": ["MET-002482"],
      "idelisa": "MET-002449",
      "chargeassay": "MET-002469",
      "sec": "MET-003588",
      "rcesds": "MET-003589",
      "titer": "MET-003496",
      "chopelisa": "MET-003758",
      "proaelisa": "MET-001363",
      "bioassayLink": ["http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d823d5586/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d80bf626c"],
      "idelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d80eed655/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d80a86ccc",
      "chargeassayLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8290fd9a/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d80b5435a",
      "secLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d828f107f/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d826b9305",
      "rcesdsLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d828ee5ac/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d826b94e4",
      "titerLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82437073/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d82437073",
      "chopelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82dd6006/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d82dd6006",
      "proaelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8256d09f/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d801675bf",
      "process_lead": "Ryan Soderquist",
      "analytical_lead": "Amanda Miller",
      "formulation_lead": "Lindsay Fay",
      "upstream_lead": "Craig Zupke",
      "downstream_lead": "Dorothy Copeland ",
      "fileLink": "",
      "allfilters": "tile monoclonal igg2 kappalc active cpd irritableboweldisease"
    },
    {
      "molecule_name": "AMG 191",
      "status_text": "Inactive",
      "stage_text": "FIH",
      "tile_icon": "igg1kappa.svg",
      "alternate_names": "Anti c-Kit Antibody",
      "molecule_illustration": "amg191.png",
      "pstformed": "6/2006",
      "pstraw": "200606",
      "class1": "IgG1",
      "class2": "Kappa LC",
      "modality": "Monoclonal Antibody",
      "extinctioncoeff": "1.4",
      "peptidemw": "145,287",
      "pi": "7.6",
      "summary_text": "Based on the putative structure of IgG1 antibodies, the protein is composed of two heavy chains, and two light chains.  There are 12 intra-molecular disulfide bonds, and four inter-molecular disulfide bonds.  The cysteine pairings in the figure have been confirmed and are those expected for IgG1 antibodies.  AMG 191 is an aglycosylated antibody with a substitution of N297 to Q297 in the 2nd constant domain of the heavy chain.",
      "heavychain": "QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGVIYSGNGDTSYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARERDTRFGNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": "DIVMTQSPDSLAVSLGERATINCRASESVDIYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNNEDPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC",
      "heavychain_image": "hc_amg191.png",
      "lightchain_image": "lc_amg191.png",
      "sequence_legend": "legend_amg191.png",
      "formulation_text": "10mM Sodium Acetate, 9% sucrose, 0.004% polysorbate 20, pH 5.2",
      "target_text": "Stem Cell Factor (SCF) signaling via its receptor, c-Kit, is vital for mast cell development, function and survival.  It is proposed that binding of AMG191 to the c-Kit receptor can result in the depletion of both basal and activated mast cells in inflammatory diseases by inhibiting SCF binding to this receptor.",
      "therapeuticindications_text": "Idiopathic Pulmonary Fibrosis (IPF)",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": ["MET-001811"],
      "idelisa": "",
      "chargeassay": "MET-001810",
      "sec": "MET-001812",
      "rcesds": "MET-001814",
      "titer": "MET-000195",
      "chopelisa": "A01723",
      "proaelisa": "72905-51",
      "bioassayLink": ["http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d80c88864/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d803ad48f"],
      "idelisaLink": "",
      "chargeassayLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d80c8fd55/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d803ac53d",
      "secLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d80c8d4c6/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d803ad5fc",
      "rcesdsLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8098fa16/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d803b8a0f",
      "titerLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d81177033/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d80114fbe",
      "chopelisaLink": "",
      "proaelisaLink": "",
      "process_lead": "Mike Vandiver",
      "analytical_lead": "Laurie Jones",
      "formulation_lead": "Gerd Kleeman",
      "upstream_lead": "Alison Bianch",
      "downstream_lead": "Ron Gillespie",
      "fileLink": "",
      "allfilters": "tile inactive fih monoclonal igg1 kappalc idiopathicpulmonaryfibrosis"
    },
    {
      "molecule_name": "AMG 224",
      "status_text": "Active in Development",
      "stage_text": "FIH",
      "tile_icon": "adc_igg1lambda.svg",
      "alternate_names": "Anti-BCMA Antibody",
      "molecule_illustration": "amg224.png",
      "pstformed": "11/2012",
      "pstraw": "201211",
      "class1": "IgG1",
      "class2": "Lambda LC",
      "modality": "Antibody-Drug Conjugate",
      "extinctioncoeff": "1.5",
      "peptidemw": "146,588",
      "pi": "8.7",
      "summary_text": "AMG 224 mAb is composed of two heavy chains and two light chains.  Disulfide bonds are shown in thin lines.  There is a single glycosylation site located on the second constant domain of each heavy chain (N303). AMG 224 DP will be naked mAb conjugated to the anti-tubulin agent is N2’-deacetyl-N-2’(3-mercapto-1-oxopropyl)-maytansine (DM1) via the linker 4-[N-maleimidomethyl] cyclohexane-1-carboxylate (SMCC). The MAR (maytansinoid antibody ratio) is 3.5.",
      "heavychain": "EVQLVESGGGLVKPGGSLRLSCAASGFTFGDYALSWFRQAPGKGLEWVGVSRSKAYGGTTDYAASVKGRFTISRDDSKSTAYLQMNSLKTEDTAVYYCASSGYSSGWTPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": "QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIFNYHQRPSGVPDRFSGSKSGSSASLAISGLQSEDEADYYCAAWDDSLNGWVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS",
      "heavychain_image": "hc_amg224.png",
      "lightchain_image": "lc_amg224.png",
      "sequence_legend": "%$*#",
      "formulation_text": "10 mM sodium acetate, 9.0% (w/v) sucrose, 0.004% (w/v) polysorbate 20, pH 5.2",
      "target_text": "224 binds to BCMA expressed on Multiple Myeloma tumor cells (where it is internalized) and delivers the DM1 payload, which induces on-mechanism mitotic arrest and apoptosis.",
      "therapeuticindications_text": "Multiple Myeloma (MM)",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": ["MET-003352"],
      "idelisa": "MET-003370",
      "chargeassay": "MET-003391",
      "sec": "MET-002933",
      "rcesds": "MET-001648",
      "titer": "MET-003271",
      "chopelisa": "MET-000180",
      "proaelisa": "MET-001363",
      "bioassayLink": ["http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d829de34e/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d821be52e"],
      "idelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82e5dc98/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d82215800",
      "chargeassayLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82e6db4d/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d8227afff",
      "secLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d821e5b9a/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d819c2319",
      "rcesdsLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d819ee91b/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d802016e4",
      "titerLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d821f2498/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d81ec636d",
      "chopelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8219023e/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d80114d79",
      "proaelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8256d09f/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d801675bf",
      "process_lead": "Sperry Brown",
      "analytical_lead": "Quanzhou Luo",
      "formulation_lead": "Wenjin Cao",
      "upstream_lead": "Todd Luman",
      "downstream_lead": "Huanchun Cui",
      "fileLink": "",
      "allfilters": "tile adc igg1 active fih lambdalc multiplemyeloma"
    },
    {
      "molecule_name": "AMG 282",
      "status_text": "Active in Development",
      "stage_text": "CFD",
      "tile_icon": "igg2kappa.svg",
      "alternate_names": "Anti-ST2 Antibody",
      "molecule_illustration": "amg282.png",
      "pstformed": "9/2011",
      "pstraw": "201109",
      "class1": "IgG2",
      "class2": "Kappa LC",
      "modality": "Monoclonal Antibody",
      "extinctioncoeff": "1.5",
      "peptidemw": "147,623",
      "pi": "6.8",
      "summary_text": "AMG 282 is composed of two heavy chains and two light chains.  There are 12 inter-molecular disulfide bonds and 6 inter-molecular disulfide bonds.  There is a single glycosylation site located on the CH2 domain at N297.",
      "heavychain_image": "hc_amg282.png",
      "lightchain_image": "lc_amg282.png",
      "heavychain": "EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYWIGWVRQMPGKGLEWMGIIYPGNSDTRFSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHGTSSDYYGLDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": "DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQDDNFPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC",
      "sequence_legend": "%$*#",
      "formulation_text": "15 mM sodium acetate, 9% (w/v) sucrose, 0.01% (w/v) polysorbate 20, pH 5.2",
      "target_text": "IL-33 signals through a receptor complex on inflammatory cells that reside in the lung and contain the primary binding receptor ST2 and the co-receptor IL-1R accessory protein (AcP).  Binding of IL-33 to ST2 signals the release of IL-5 cytokine, MAP kinases and NF-kB.  AMG 282 binds to ST2 and blocks the binding of IL-33, therefore, preventing signaling",
      "therapeuticindications_text": "Asthma",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": ["MET-003265"],
      "idelisa": "",
      "chargeassay": "MET-003238",
      "sec": "MET-002933",
      "rcesds": "MET-001648",
      "titer": "TP-001271",
      "chopelisa": "MET-000180",
      "proaelisa": "MET-001363",
      "bioassayLink": ["http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8224c87c/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d81df3764"],
      "idelisaLink": "",
      "chargeassayLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d821e602b/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d81cda070",
      "secLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d821e5b9a/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d819c2319",
      "rcesdsLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d819ee91b/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d802016e4",
      "titerLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d81c2c28b/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d81a4d556",
      "chopelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8219023e/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d80114d79",
      "proaelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8256d09f/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d801675bf",
      "process_lead": "Alison Wallace",
      "analytical_lead": "Catherine Eakin",
      "formulation_lead": "Feng He",
      "upstream_lead": "Mirna Mujacic",
      "downstream_lead": "John Skonier",
      "fileLink": "",
      "allfilters": "tile monoclonal igg2 kappalc active cfd asthma"
    },
    {
      "molecule_name": "AMG 287",
      "status_text": "Active in Development",
      "stage_text": "FIH",
      "tile_icon": "igg2lambda.svg",
      "alternate_names": "bklotho/FGFR1c Antibody",
      "molecule_illustration": "amg287.png",
      "pstformed": "9/2011",
      "pstraw": "201109",
      "class1": "IgG2",
      "class2": "Lambda LC",
      "modality": "Monoclonal Antibody",
      "extinctioncoeff": "1.4",
      "peptidemw": "146,957",
      "pi": "6.8",
      "summary_text": "AMG 287 is composed of two heavy chains and two light chains. Disulfide bonds are shown in thin lines. There is a single glycosylated site located on the second constant domain of each heavy chain (N300, shown in blue).",
      "heavychain": "QVTLKESGPVLVKPTETLTLTCTVSGFSLNNARMGVSWIRQPPGKALEWLAHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLIMTNMDPVDTATYYCARSVVTGGYYYDGMDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": "SYVLTQPPSVSVAPGQTARITCGGNNIGSESVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDGNSDHVVFGGGTKLTVLGQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS",
      "heavychain_image": "hc_amg287.png",
      "lightchain_image": "lc_amg287.png",
      "sequence_legend": "legend_amg162.png",
      "formulation_text": "10 mM sodium acetate, 9% (w/v) sucrose, 0.01% PS-20, pH 5.8",
      "target_text": "AMG 287 activates bklotho/FGFR1c; the main receptor for Fibroblast Growth Factor 21 (FGF21). FGF-21 plays an important role in the regulation of glucose, lipid metabolism and energy balance. Activation of the FGF21 pathway may offer key advantages in the treatment of type 2 diabetes, obesity and dyslipidemia in human. AMG 287 is an agonistic antibody for this pathway with no risk of immunogenicity to endogenous FGF21.",
      "therapeuticindications_text": "Type II diabetes",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": [""],
      "idelisa": "",
      "chargeassay": "",
      "sec": "MET-002933",
      "rcesds": "MET-001648",
      "titer": "MET-003271",
      "chopelisa": "MET-000180",
      "proaelisa": "MET-001363",
      "bioassayLink": [""],
      "idelisaLink": "",
      "chargeassayLink": "",
      "secLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d821e5b9a/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d819c2319",
      "rcesdsLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d819ee91b/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d802016e4",
      "titerLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d821f2498/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d81ec636d",
      "chopelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8219023e/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d80114d79",
      "proaelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8256d09f/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d801675bf",
      "process_lead": "Gang Huang",
      "analytical_lead": "Suminda Hapaurachchi",
      "formulation_lead": "Joon Huh",
      "upstream_lead": "Kristi Daris",
      "downstream_lead": "Michael Shearer",
      "fileLink": "",
      "allfilters": "tile monoclonal igg2 lambdalc fih active typeiidiabetes"
    },
    {
      "molecule_name": "AMG 301",
      "status_text": "Active in Development",
      "stage_text": "Reagent Approach",
      "tile_icon": "igg1kappa.svg",
      "alternate_names": "Anti-PAC1 Antibody",
      "molecule_illustration": "amg301.png",
      "pstformed": "12/2013",
      "pstraw": "201312",
      "class1": "IgG1",
      "class2": "Kappa LC",
      "modality": "Monoclonal Antibody",
      "extinctioncoeff": "1.4",
      "peptidemw": "144,924",
      "pi": "8.9",
      "summary_text": "AMG 301 is a kappa-LC IgG1 based on the SEFL (stable effector-functionless) framework.  The SEFL framework is based on a mutation of the consensus glycosylation site (NST) in the CH2 to a non-consensus motif (GST).",
      "heavychain": "QVQLVESGAEVVKPGASVKVSCKASGFTFSRFAMHWVRQAPGQGLEWMGVISYDGGNKYYAESVKGRVTMTRDTSTSTLYMELSSLRSEDTAVYYCARGYDVLTGYPDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": "DIQLTQSPSFLSASVGDRVTITCRASQSIGRSLHWYQQKPGKAPKLLIKYASQSLSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCHQSSRLPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC",
      "heavychain_image": "hc_amg301.png",
      "lightchain_image": "lc_amg301.png",
      "sequence_legend": "%$*#",
      "formulation_text": "70mg/mL in 10mM sodium acetate, 9% sucrose 0.01% polysorbate 80, pH 5.2",
      "target_text": "AMG 301 is an antagonist antibody targeted against the PAC1 receptor.  Endogenous activation of PAC1 by PACAP is implicated in the migraine pathway.",
      "therapeuticindications_text": "Migraine",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": ["MET-003611"],
      "idelisa": "",
      "chargeassay": "MET-003609",
      "sec": "MET-002933",
      "rcesds": "MET-001648",
      "titer": "TP-001271",
      "chopelisa": "MET-000180",
      "proaelisa": "MET-001363",
      "bioassayLink": ["http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d828cb809/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d827f392e"],
      "idelisaLink": "",
      "chargeassayLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d828dbf0a/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d827d4c9a",
      "secLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d821e5b9a/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d819c2319",
      "rcesdsLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d819ee91b/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d802016e4",
      "titerLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d81c2c28b/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d81a4d556",
      "chopelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8219023e/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d80114d79",
      "proaelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8256d09f/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d801675bf",
      "process_lead": "Ron Gillespie",
      "analytical_lead": "Ken Prentice",
      "formulation_lead": "Chris Sloey",
      "upstream_lead": "Heather Nunn",
      "downstream_lead": "Thao Nguyen",
      "fileLink": "",
      "allfilters": "tile monoclonal igg1 kappalc active reagentapproach migraine"
    },
    {
      "molecule_name": "AMG 303",
      "status_text": "Inactive",
      "stage_text": "FIH",
      "tile_icon": "igg2kappa.svg",
      "alternate_names": "Anti-OX40L",
      "molecule_illustration": "amg303.png",
      "pstformed": "9/2003",
      "pstraw": "200309",
      "class1": "IgG2",
      "class2": "Kappa LC",
      "modality": "Monoclonal Antibody",
      "extinctioncoeff": "1.5",
      "peptidemw": "150,875",
      "pi": "8.8",
      "summary_text": "AMG303 (IgG2) is composed of two heavy chains and two light chains.  There are 12 intra-molecular disulfide bonds and 6 inter-molecular disulfides.  Indicated cysteine pairings in hinge region are those expected for IgG2 antibodies, those outside of hinge are confirmed.  AMG303 has one N-linked glycosylation site at N-303 in the second constant domain of the heavy chain (CH2).",
      "heavychain": "pEVQLVESGGGVVQPGRSLRLSCAASGFTFSFYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGGYDYVWGSYRRNSDFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG",
      "lightchain": "DIVMTQTPLSSPVTLGQPASISCRSSQSLVHSDGNTYLSWLQQRPGQPPRLLIYKKFNRFSGVPDRFSGSGAGTDFTLKISRVEAEDVGVYYCMQATQIPLTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC",
      "heavychain_image": "hc_amg303.png",
      "lightchain_image": "lc_amg303.png",
      "sequence_legend": "%$*#",
      "formulation_text": "10mM sodium acetate, 9% sucrose, pH 5.2, 0.004% PS20",
      "target_text": "AMG303 binds to OX40L and neutralizes cellular and biochemical interaction of OX40 to OX40L.  This blockade of OX40 to OX40L by AMG 303 ameliorates CD4+ T-cell mediated autoimmune diseases.",
      "therapeuticindications_text": "Inflammatory Bowel Disease (IBD)",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": ["AWA-AS-303M04"],
      "idelisa": "",
      "chargeassay": "AWA-AS-303M03",
      "sec": "AWA-AS-303M01",
      "rcesds": "AWA-AS-303M02",
      "titer": "AWA-AS-M06",
      "chopelisa": "AWA-AS-M05",
      "proaelisa": "AWA-AS-M04",
      "bioassayLink": [""],
      "idelisaLink": "",
      "chargeassayLink": "",
      "secLink": "",
      "rcesdsLink": "",
      "titerLink": "",
      "chopelisaLink": "",
      "proaelisaLink": "",
      "process_lead": "Abhinav Shukla",
      "analytical_lead": "Alison Wallace",
      "formulation_lead": "Tim Osslund",
      "upstream_lead": "Dan Leiske",
      "downstream_lead": "Stephen Trimble",
      "fileLink": "",
      "allfilters": "tile monoclonal igg2 kappalc inactive fih irritableboweldisease" 
    },
    {
      "molecule_name": "AMG 317",
      "status_text": "Inactive",
      "stage_text": "FIH",
      "tile_icon": "igg2kappa.svg",
      "alternate_names": "Anti-IL4R",
      "molecule_illustration": "amg317.png",
      "pstformed": "",
      "pstraw": "0",
      "class1": "IgG2",
      "class2": "Kappa LC",
      "modality": "Monoclonal Antibody",
      "extinctioncoeff": "1.5",
      "peptidemw": "143,733",
      "pi": "8",
      "summary_text": "Based on knowledge of IgG2 structure, the protein is assumed to be composed of two heavy chains, and two light chains.  There are 12 intra-molecular disufide bonds, and 6 inter-molecular disulfide bonds.  AMG317 is glycosylated, the site presumably in the CH2",
      "heavychain": "EVQLVESGGGLVQPGGSLRLSCAASGFTFSRNAMFWVRQAPGKGLEWVSGIGTGGATSYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGRYYFPWWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": "EIVLTQSPGTLSLSPGERATLSCRASQSVSNSYLAWYQQKPGQAPRLLIYGASSRAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDHSAGWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC",
      "heavychain_image": "hc_amg317.png",
      "lightchain_image": "lc_amg317.png",
      "sequence_legend": "%$*#",
      "formulation_text": "50 mM acetate, 5% sorbitol, 0.004% polysorbate 20, pH 5",
      "target_text": "AMG 317 is an antibody against IL-4R that prevents binding of IL-4 and IL-13 cytokines",
      "therapeuticindications_text": "Asthma",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": ["T-2029"],
      "idelisa": "",
      "chargeassay": "",
      "sec": "",
      "rcesds": "",
      "titer": "",
      "chopelisa": "",
      "proaelisa": "",
      "bioassayLink": [""],
      "idelisaLink": "",
      "chargeassayLink": "",
      "secLink": "",
      "rcesdsLink": "",
      "titerLink": "",
      "chopelisaLink": "",
      "proaelisaLink": "",
      "process_lead": "Arvia Morris",
      "analytical_lead": "Bob Bailey",
      "formulation_lead": "Andrea Wong",
      "upstream_lead": "Arvia Morris",
      "downstream_lead": "Josh Peterson",
      "fileLink": "",
      "allfilters": "tile monoclonal igg2 kappalc inactive fih asthma"
    },
    {
      "molecule_name": "AMG 330",
      "status_text": "Active in Development",
      "stage_text": "FIH",
      "tile_icon": "bitecd3.png",
      "alternate_names": "Anti-CD33",
      "molecule_illustration": "amg330.png",
      "pstformed": "04/2012",
      "pstraw": "201204",
      "class1": "CD3",
      "class2": "        ",
      "modality": "BiTe",
      "extinctioncoeff": "2.3",
      "peptidemw": "54,323",
      "pi": "8.4",
      "summary_text": "Based on the putative structure of BiTEs, the protein is composed of a single chain containing four intra-molecular disulfide bonds. The cysteine pairings in the figure are those expected for BiTEs. Flexible linker sequences are shown in black; a 6xHis tag is present at the C-terminus. AMG 330 has no predicted glycosylation sites.",
      "heavychain": "QVQLVQSGAEVKKPGESVKVSCKASGYTFTNYGMNWVKQAPGQGLEWMGWINTYTGEPTYADKFQGRVTMTTDTSTSTAYMEIRNLGGDDTAVYYCARWSWSDGYYVYFDYWGQGTSVTVSSGGGGSGGGGSGGGGSDIVMTQSPDSLTVSLGERTTINCKSSQSVLDSSTNKNSLAWYQQKPGQPPKLLLSWASTRESGIPDRFSGSGSGTDFTLTIDSPQPEDSATYYCQQSAHFPITFGQGTRLEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLHHHHHH",
      "lightchain": "%$*#",
      "heavychain_image": "hc_amg330.png",
      "lightchain_image": "%$*#",
      "sequence_legend": "%$*#",
      "formulation_text": "10 mM potassium phosphate, 1% (w/v) sulfobutylether beta-cyclodextrin, (aka Captisol™), 8% (w/v) sucrose, 0.01% polysorbate 80, pH 6.0",
      "target_text": "",
      "therapeuticindications_text": "Oncology: Acute Myeloid Leukemia (AML)",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": [""],
      "idelisa": "MET-003487",
      "chargeassay": "MET-003526",
      "sec": "MET-003520",
      "rcesds": "MET-003521",
      "titer": "MDR-001109",
      "chopelisa": "",
      "proaelisa": "",
      "bioassayLink": [""],
      "idelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82d64132/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d82422fde",
      "chargeassayLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82d35d32/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d8248a341",
      "secLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82ebd798/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d824793b3",
      "rcesdsLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82d33c00/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d8247f5a4",
      "titerLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82aa9d58/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d826e498d",
      "chopelisaLink": "",
      "proaelisaLink": "",
      "process_lead": "Thomas Böhm and Rüdiger Neef",
      "analytical_lead": "Sonya Schermann",
      "formulation_lead": "Cornelius Pompe",
      "upstream_lead": "Susann Berthold",
      "downstream_lead": "Uwe Syring",
      "fileLink": "",
      "allfilters": "tile bite cd3 active fih oncology"
    },
    {
      "molecule_name": "AMG 334",
      "status_text": "Active in Development",
      "stage_text": "CPD",
      "tile_icon": "igg2lambda.svg",
      "alternate_names": "Anti-CGRPR",
      "molecule_illustration": "amg334.png",
      "pstformed": "7/2010",
      "pstraw": "201007",
      "class1": "IgG2",
      "class2": "Lambda LC",
      "modality": "Monoclonal Antibody",
      "extinctioncoeff": "1.5",
      "peptidemw": "148,764",
      "pi": "9.1",
      "summary_text": "AMG 334 is composed of two heavy chains of the IgG2 subclass and two light chains of the lambda (l) subclass. The schematic shown in Figure is a canonical structure for an IgG2. There are 12 intra-chain disulfide bonds and 6 inter-chain disulfide bonds. There is a single glycosylated site located on the second constant domain of each heavy chain (N306).",
      "heavychain": "QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAVISFDGSIKYSVDSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCARDRLNYYDSSGYYHYKYYGMAVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": "QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSTTLGITGLQTGDEADYYCGTWDSRLSAVVFGGGTKLTVLGQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS ",
      "heavychain_image": "hc_amg334.png",
      "lightchain_image": "lc_amg334.png",
      "sequence_legend": "legend_amg334.png",
      "formulation_text": "15 mM sodium acetate, 8.2% (w/v) sucrose, 0.01% (w/v) polysorbate 80",
      "target_text": "AMG 334 is a fully human monoclonal immunoglobulin (IgG2) that specifically binds to the extracellular domains of the calcitonin gene-related peptide receptor (CGRP-R) and prevent its interaction with the neuropetide, CGRP. CGRP is expressed in and released by sensory nerves and acts as a potent vasodilator upon binding to its corresponding receptor, CGRP-R. CGRP has been implicated in migraines and CGRP levels are elevated in the blood during migraine attack.",
      "therapeuticindications_text": "Migraine",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": ["MET-002764"],
      "idelisa": "MET-002767",
      "chargeassay": "MET-002765",
      "sec": "MET-002933",
      "rcesds": "MET-001648",
      "titer": "TP-001271",
      "chopelisa": "MET-000180",
      "proaelisa": "MET-001363",
      "bioassayLink": ["http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d827ceceb/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d815ec189"],
      "idelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82cf0a78/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d8162f88f",
      "chargeassayLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8197b4ae/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d8160da2c",
      "secLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d821e5b9a/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d819c2319",
      "rcesdsLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d819ee91b/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d802016e4",
      "titerLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d81c2c28b/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d81a4d556",
      "chopelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8219023e/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d80114d79",
      "proaelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8256d09f/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d801675bf",
      "process_lead": "Kurt Kunas",
      "analytical_lead": "Suminda Hapuarachchi",
      "formulation_lead": "Matthew Fesinmeyer",
      "upstream_lead": "Kurt Kunas",
      "downstream_lead": "Jason Newmark",
      "fileLink": "",
      "allfilters": "tile monoclonal igg2 lambdalc cpd active migraine"
    },
    {
      "molecule_name": "AMG 391",
      "status_text": "Inactive",
      "stage_text": "FIH",
      "tile_icon": "igg2kappa.svg",
      "alternate_names": "Anti-GM-CSF Antibody",
      "molecule_illustration": "amg391.png",
      "pstformed": "12/2006",
      "pstraw": "200612",
      "class1": "IgG2",
      "class2": "Kappa LC",
      "modality": "Monoclonal Antibody",
      "extinctioncoeff": "1.5",
      "peptidemw": "149,821",
      "pi": "7.8",
      "summary_text": "Based on the putative structure of IgG2 antibodies, the protein is likely composed of two heavy chains, and two light chains.  There should be 12 intra-molecular disufide bonds, and 6 inter-molecular disulfide bonds.  Indicated cysteine pairings in hinge region are those expected for IgG2 antibodies.  AMG 391 has one N-linked glycosylation site at N-296 in the second constant domain of the heavy chain (CH2).",
      "heavychain": "QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWINPNSGGTNSAQKFRGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREGGYSYGYFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": "DIVLTQSPDSLAVSLGERATINCKSSQSILYSSSNENFLTWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQPEDVAVYYCQQYFSVFRTFGQGTRVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC",
      "heavychain_image": "hc_amg391.png",
      "lightchain_image": "lc_amg391.png",
      "sequence_legend": "%$*#",
      "formulation_text": "10mM sodium acetate, 9% sucrose, pH 5.2",
      "target_text": "AMG 391 targets GM-CSF (Granulocyte-macrophage colony-stimulating factor), a critical inflammatory cytokine.  Inhibition of GM-CSF activity in MS patients will reduce Central Nervous System inflammation and consequently reduce the relapse rate and progression of neurological disability.",
      "therapeuticindications_text": "Multiple Sclerosis",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": [""],
      "idelisa": "",
      "chargeassay": "",
      "sec": "",
      "rcesds": "",
      "titer": "",
      "chopelisa": "",
      "proaelisa": "",
      "bioassayLink": [""],
      "idelisaLink": "",
      "chargeassayLink": "",
      "secLink": "",
      "rcesdsLink": "",
      "titerLink": "",
      "chopelisaLink": "",
      "proaelisaLink": "",
      "process_lead": "Alison Wallace",
      "analytical_lead": "Alison Wallace",
      "formulation_lead": "Gerd Kleemann",
      "upstream_lead": "Martin Allen",
      "downstream_lead": "Lisa Connell-Crowley",
      "fileLink": "",
      "allfilters": "tile monoclonal igg2 kappalc inactive fih multiplesclerosis"
    },
    {
      "molecule_name": "AMG 479",
      "status_text": "Inactive",
      "stage_text": "Post-CPD",
      "tile_icon": "igg1kappa.svg",
      "alternate_names": "Anti-IGF-1R, Ganitumab",
      "molecule_illustration": "amg479.png",
      "pstformed": "7/2003",
      "pstraw": "200307",
      "class1": "IgG1",
      "class2": "Kappa LC",
      "modality": "Monoclonal Antibody",
      "extinctioncoeff": "1.6",
      "peptidemw": "145,658",
      "pi": "8.9",
      "summary_text": "Based on the putative structure of IgG1 antibodies, the protein is composed of two heavy chains, and two light chains.  There are 12 intra-molecular disufide bonds, and four inter-molecular disulfide bonds.  The cysteine pairings in the figure are those expected for IgG1 antibodies.  AMG 479 is glycosylated on the 2nd constant domain of the heavy chain Asn299.",
      "heavychain": "QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARWTGRTDAFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": "DVVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC",
      "heavychain_image": "hc_amg479.png",
      "lightchain_image": "lc_amg479.png",
      "sequence_legend": "%$*#",
      "formulation_text": "10 mM sodium acetate, 5% sorbitol, 0.004% polysorbate 20, pH5.2",
      "target_text": "AMG 479 binds to the extra cellular domain of the insulin-like growth factor I receptor (IGF-1R), a transmembrane receptor tyrosine kinase.  Disruption of IGF-1 binding to its receptor could potentiate the apoptotic effect of standard cancer therapy, as well as enhancing the activity of therapeutics targeted toward receptor tyrosine kinases (e.g. HER-2, EGFR, KDR).",
      "therapeuticindications_text": "Oncology: Pancreatic cancer, metastatic colorectal cancer, ovarian cancer and SCLC",
      "milestones_text": [
            "PST Formed 6/2003",
            "GLP tox production 7/2004",
            "GMP production 11/2004",
            "IND filing 05/2005",
            "Phase I clinical trial 10/2005",
            "CPD Portal Q2/2007",
            "PCI Gate Q1/2010"
      ],
      "issueschallenges_text": "",
      "bioassay": ["MET-001604"],
      "idelisa": "MET-002324",
      "chargeassay": "MET-001603",
      "sec": "MET-001591",
      "rcesds": "MET-002361",
      "titer": "MET-000195",
      "chopelisa": "MET-002529",
      "proaelisa": "MET-002528",
      "bioassayLink": ["http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82d8b7a9/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d801bdc95"],
      "idelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d81b33e91/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d806559d8",
      "chargeassayLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d81376866/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d801bdc85",
      "secLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d80fb21ed/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d801bdab9",
      "rcesdsLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d81480636/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d8073fe27",
      "titerLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d81177033/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d80114fbe",
      "chopelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d80f03799/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d80e2c12b",
      "proaelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d80f03638/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d80e2c078",
      "process_lead": "Randal Bass",
      "analytical_lead": "Alison Gillespie",
      "formulation_lead": "Sampath Krishnan",
      "upstream_lead": "Brad Dell",
      "downstream_lead": "Joanne Reeder",
      "fileLink": "",
      "allfilters": "tile monoclonal igg1 kappalc inactive postcpd oncology"
    },
    {
      "molecule_name": "AMG 557",
      "status_text": "Active in Development",
      "stage_text": "CFD",
      "tile_icon": "igg2kappa.svg",
      "alternate_names": "Anti-B7RP-1",
      "molecule_illustration": "amg557.png",
      "pstformed": "11/2004",
      "pstraw": "200411",
      "class1": "IgG2",
      "class2": "Kappa LC",
      "modality": "Monoclonal Antibody",
      "extinctioncoeff": "1.6",
      "peptidemw": "148,046",
      "pi": "7.5",
      "summary_text": "AMG 557 is an IgG2 molecule, composed of two heavy chains, and two light chains.  There are 12 intramolecular disulfide bonds, and six intermolecular disulfide bonds.  AMG 557 has a single glycosylation site located on the 2nd constant domain of each heavy chain (N297 glycan).",
      "heavychain": "EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVAYIKQDGNEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGILWFGDLPTFWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": "DIQMTQSPSSLSASVGDRVTITCRASQGISNWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDSYPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC",
      "heavychain_image": "hc_amg557.png",
      "lightchain_image": "lc_amg557.png",
      "sequence_legend": "legend_amg162.png",
      "formulation_text": "10 mM sodium acetate, 9% sucrose, 0.004% polysorbate 20, pH 5.2",
      "target_text": "B7related protein 1 (B7RP1) is a receptor on antigen presenting cells which binds to inducible costimulator (ICOS) - a membrane bound protein expressed by T cells.  This B7RP1/ICOS binding is part of a costimulation pathway that plays a role in the inflammatory response.  The purpose of this project is to develop a mAb that binds to B7RP1 and blocks the binding to ICOS, inhibiting an inflammatory response.",
      "therapeuticindications_text": "Inflammation: Lupus (SLE)",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": ["A01523"],
      "idelisa": "",
      "chargeassay": "A01517",
      "sec": "A01519",
      "rcesds": "A01515",
      "titer": "A01502",
      "chopelisa": "A01514",
      "proaelisa": "",
      "bioassayLink": [""],
      "idelisaLink": "",
      "chargeassayLink": "",
      "secLink": "",
      "rcesdsLink": "",
      "titerLink": "",
      "chopelisaLink": "",
      "proaelisaLink": "",
      "process_lead": "Jerry Yang",
      "analytical_lead": "Anil Raghani",
      "formulation_lead": "Ge Jiang",
      "upstream_lead": "",
      "downstream_lead": "",
      "fileLink": "",
      "allfilters": "tile monoclonal igg2 kappalc active cfd lupus"
    },
    {
      "molecule_name": "AMG 563",
      "status_text": "Inactive",
      "stage_text": "FIH",
      "tile_icon": "igg2lambda.svg",
      "alternate_names": "Anti-CD30L Antibody",
      "molecule_illustration": "amg563.png",
      "pstformed": "10/2004",
      "pstraw": "200410",
      "class1": "IgG2",
      "class2": "Lambda LC",
      "modality": "Monoclonal Antibody",
      "extinctioncoeff": "1.5",
      "peptidemw": "142,678",
      "pi": "6.6",
      "summary_text": "The protein is composed of two heavy chains and two light chains. It is predicted that the disulfide structure follows that of other IgG2 molecules with 12 intra-chain disulfides and 6 inter-chain disulfides.  AMG 563 has one glycosylation site located on the 2nd constant domain of the heavy chain (N292).",
      "heavychain": "QLQLVESGGGLVKPGGSLRLSCAASGLPFSDYYMTWIRQAPGKGLEWVSYINGDDSDIQYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGMEWLREWGQGTMVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": "SSELTQPPSVSVSPGQTARITCSGDALSKEYAYWYQQKPGQAPVLVIYKDNQRPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCQSADSSGLSVIFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS",
      "heavychain_image": "hc_amg563.png",
      "lightchain_image": "lc_amg563.png",
      "sequence_legend": "%$*#",
      "formulation_text": "10 mM potassium phosphate, 3.4% (161 mM)  L-arginine HCl, 0.004% (w/v)  polysorbate 20, pH 7.6",
      "target_text": "AMG563 is a phage-derived, fully human anti-human CD30L antibody that binds to native human and cynomolgus CD30L and blocks the biological function of both ligands in cell-based assays. CD30L and CD30 are interacting cell surface glycoproteins that are members of the TNF and TNFR superfamilies, respectively. CD30L/CD30 interactions promote class-switched antibody responses. In vivo treatment with an anti-mouse CD30L surrogate antibody inhibits the development or progression of disease in a number of mouse models of autoimmunity. In models with a strong humoral immune component, inhibition of disease correlates with inhibition of the disease-associated antibody response.",
      "therapeuticindications_text": "Asthma and Lupus",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": [""],
      "idelisa": "",
      "chargeassay": "",
      "sec": "",
      "rcesds": "",
      "titer": "AWA-AS-M06",
      "chopelisa": "AWA-AS-M05",
      "proaelisa": "AWA-AS-M04",
      "bioassayLink": [""],
      "idelisaLink": "",
      "chargeassayLink": "",
      "secLink": "",
      "rcesdsLink": "",
      "titerLink": "",
      "chopelisaLink": "",
      "proaelisaLink": "",
      "process_lead": "Martin Allen",
      "analytical_lead": "Theresa Martinez",
      "formulation_lead": "Deirdre Piedmonte",
      "upstream_lead": "Neil Kitchen",
      "downstream_lead": "Joanne Reeder",
      "fileLink": "",
      "allfilters": "tile monoclonal igg2 lambdalc inactive fih asthma lupus"
    },
      {
      "molecule_name": "AMG 570",
      "status_text": "Reagent Approach",
      "stage_text": "FIH",
      "tile_icon": "igg2kappa.svg",
      "alternate_names": "aB7RP-1/aBAFF Bispecific mAb",
      "molecule_illustration": "amg570.png",
      "pstformed": "11/2013",
      "pstraw": "201311",
      "class1": "IgG2",
      "class2": "Kappa LC",
      "modality": "Bispecific",
      "extinctioncoeff": "1.7",
      "peptidemw": "158,134",
      "pi": "8.0",
      "summary_text": "",
      "heavychain": "EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVAYIKQDGNEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGILWFGDLPTFWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGGLPGCKWDLLIKQWVCDPLGSGSATGGSGSVASSGSGSATHLLPGCKWDLLIKQWVCDPL",
      "lightchain": "DIQMTQSPSSLSASVGDRVTITCRASQGISNWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDSYPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC",
      "heavychain_image": "hc_amg570.png",
      "lightchain_image": "lc_amg570.png",
      "sequence_legend": "legend_amg570.png",
      "formulation_text": "10 mM sodium acetate, 9% (w/v) sucrose, 0.01% (w/v) polysorbate 80, pH 5.2",
      "target_text": "SLE pathogenesis involves aberrant T cells and B cells.  B7RP-1-ICOS pathway is critical to T cell development and T memory cell homeostasis; whereas BAFF is critical for B cell survival.  The anit-B7RP-1 mAb component is designed to function as a T cell modulator with the anti-BAFF component to inhibit B cell survival.",
      "therapeuticindications_text": "Systemic Lupus Erythematosus (SLE)",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": ["MET-003700 (aB7RP-1)", "MET-003701 (aBAFF)"],
      "idelisa": "",
      "chargeassay": "MET-003703",
      "sec": "MET-003702",
      "rcesds": "MET-001648",
      "titer": "MET-003271",
      "chopelisa": "MET-000180",
      "proaelisa": "MET-001363",
      "bioassayLink": [""],
      "idelisaLink": "",
      "chargeassayLink": "",
      "secLink": "",
      "rcesdsLink": "",
      "titerLink": "",
      "chopelisaLink": "",
      "proaelisaLink": "",
      "process_lead": "Ken Lawson",
      "analytical_lead": "Ken Lawson",
      "formulation_lead": "Tom Dillon",
      "upstream_lead": "Tharmala Tharmalingam",
      "downstream_lead": "Rosalind Stenson",
      "fileLink": "",
      "allfilters": "tile bispecific igg2 kappalc reagentapproach lupus"
    },
    {
      "molecule_name": "AMG 575",
      "status_text": "Inactive",
      "stage_text": "FIH",
      "tile_icon": "igg2kappa.svg",
      "alternate_names": "Human Anti-p55",
      "molecule_illustration": "amg575.png",
      "pstformed": "10/2005",
      "pstraw": "200510",
      "class1": "IgG2",
      "class2": "Kappa LC",
      "modality": "Monoclonal Antibody",
      "extinctioncoeff": "1.4",
      "peptidemw": "143,678",
      "pi": "8.0",
      "summary_text": "Hu Anti-P55 (IgG2) is composed of two heavy chains, and two light chains.  There are 12 intra-molecular disulfide bonds, and 4 inter-molecular disulfide bonds.  This antibody is glycosylated presumably on the 2nd constant domain of the heavy chain.",
      "heavychain": "EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYVMSWVRQAPGKGLEWVSSISGSGLGSYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKEAHRGPFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": "EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWHQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC",
      "heavychain_image": "hc_amg575.png",
      "lightchain_image": "lc_amg575.png",
      "sequence_legend": "%$*#",
      "formulation_text": "10mM sodium acetate 9% sucrose pH5.2",
      "target_text": "Anti-TNF is a validated target for the treatment  inflammatory disease.  TNF is known to bind to two cell surface receptors; p55 and p75.  Anti-P55 or AMG 575 targets only p55 TNF receptor and have shown to inhibits pro-inflammatory function.   It does not bind to p75 TNF receptor which has been shown to play a protective function in the inflamation process.",
      "therapeuticindications_text": "Rheumatoid Arthritis (RA)",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": [""],
      "idelisa": "",
      "chargeassay": "A01678",
      "sec": "A01677",
      "rcesds": "A01679",
      "titer": "AWA-AS-M06",
      "chopelisa": "AWA-AS-M05",
      "proaelisa": "AWA-AS-M04",
      "bioassayLink": [""],
      "idelisaLink": "",
      "chargeassayLink": "",
      "secLink": "",
      "rcesdsLink": "",
      "titerLink": "",
      "chopelisaLink": "",
      "proaelisaLink": "",
      "process_lead": "Bob Bailey",
      "analytical_lead": "Duke Phan",
      "formulation_lead": "Stephen Brych",
      "upstream_lead": "Terri Aldrich",
      "downstream_lead": "John Moscariello",
      "fileLink": "",
      "allfilters": "tile monoclonal igg2 kappalc inactive fih rheumatoidarthritis"
    },
    {
      "molecule_name": "AMG 592",
      "status_text": "Active in Development",
      "stage_text": "Reagent Approach",
      "tile_icon": "fusion.png",
      "alternate_names": "IL2 Mutein",
      "molecule_illustration": "amg592.png",
      "pstformed": "10/2013",
      "pstraw": "201310",
      "class1": "",
      "class2": "",
      "modality": "Fusion Protein",
      "extinctioncoeff": "1.1",
      "peptidemw": "83,510",
      "pi": "7.9",
      "summary_text": "AMG 592 is composed of two identical polypeptide chains. Two copies of the IL2 protein and linkers exist at the C-terminus of each chain. The Fc region comprises the N-terminal portion of each chain. The disulfide bonds are shown. There are two inter-chain disulfide bonds and six intra-chain disulfide bonds. When AMG 592 is expressed in Chinese hamster ovary cells, threonine 234 (T234) from the IL-2 protein is modified with O-linked glycosylation. Three mutations are made for AMG 592 molecule and they are N77G on the Fc portion, V322K and C356A on the IL2 peptide portion.",
      "heavychain": "DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGGGSAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINKIVLELKGSETTFMCEYADETATIVEFLNRWITFAQSIISTLT",
      "lightchain": "%$*#",
      "heavychain_image": "hc_amg592.png",
      "lightchain_image": "%$*#",
      "sequence_legend": "legend_amg592.png",
      "formulation_text": "10 mM sodium acetate, 9% (w/v) sucrose, 0.01% (w/v) polysorbate 80,  pH 5.2",
      "target_text": "IL-2 is a growth factor for regulatory T cells (Tregs). Tregs are essential for suppressing deleterious inflammation. IL-2 also stimulates CD4 and CD8 effector T (Teff) and NK cells. AMG 592 (IL2 mutein) is engineered to reduce IL-2 Teff activity while retaining Tregs activity for immunosuppression.",
      "therapeuticindications_text": "Graft vs host disease (GVHD)",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": ["TP-001748"],
      "idelisa": "TP-001757",
      "chargeassay": "TP-001755",
      "sec": "TP-001733",
      "rcesds": "TP-001827",
      "titer": "MET-003271",
      "chopelisa": "MET-000180",
      "proaelisa": "MET-001363",
      "bioassayLink": ["http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82e03f5f/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d8295c6c9"],
      "idelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82ce922a/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d829e4151",
      "chargeassayLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82d0ddfe/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d829bf456",
      "secLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82d05db6/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d82908797",
      "rcesdsLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82d0de04/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d82bc434f",
      "titerLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d821f2498/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d81ec636d",
      "chopelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8219023e/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d80114d79",
      "proaelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8256d09f/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d801675bf",
      "process_lead": "Kurt Kunas",
      "analytical_lead": "Le Zhang",
      "formulation_lead": "Renuka Thirumangalathu",
      "upstream_lead": "Prince Bhebe",
      "downstream_lead": "Russell Van Buskirk",
      "fileLink": "",
      "allfilters": "tile fusion active reagentapproach graftvshost"
    },
    {
      "molecule_name": "AMG 595",
      "status_text": "Active in Development",
      "stage_text": "FIH",
      "tile_icon": "adc_igg1kappa.svg",
      "alternate_names": "Anti-EGFRvIII",
      "molecule_illustration": "amg595.png",
      "pstformed": "2/2012",
      "pstraw": "201202",
      "class1": "IgG1",
      "class2": "Kappa LC",
      "modality": "Antibody-Drug Conjugate",
      "extinctioncoeff": "1.4",
      "peptidemw": "150,761",
      "pi": "8.9",
      "summary_text": "AMG 595 is composed of anti-EGFRvIII antibody with a linker linked to an anti-tubulin agent. Anti-EGFRvIII (IgG1) is composed of two heavy chains, and two light chains.  There should be 12 intra-molecular disulfide bonds, and 4 inter-molecular disulfide bonds.  The cysteine parings in the figure are those expected for IgG1 antibodies. This antibody is glycosylated on the 2nd constant domain of the heavy chain (N304 linked glycan).  The linker is 4-[N-maleimidomethyl] cyclohexane-1-carboxylate (MCC), and the anti-tubulin agent is N2’-deacetyl-N-2’(3-mercapto-1-oxopropyl)-maytansine (DM1).",
      "heavychain": "QVQLVESGGGVVQSGRSLRLSCAASGFTFRNYGMHWVRQAPGKGLEWVAVIWYDGSDKYYADSVRGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGYDILTGNPRDFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": "DTVMTQTPLSSHVTLGQPASISCRSSQSLVHSDGNTYLSWLQQRPGQPPRLLIYRISRRFSGVPDRFSGSGAGTDFTLEISRVEAEDVGVYYCMQSTHVPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC",
      "heavychain_image": "hc_amg595.png",
      "lightchain_image": "lc_amg595.png",
      "sequence_legend": "legend_amg595.png",
      "formulation_text": "10 mM sodium acetate, 9.0% (w/v) sucrose, 0.004% (w/v) polysorbate 20, pH 5.2",
      "target_text": "Mutant epidermal growth factor receptor variant III (EFGRvIII) is a constitutively activated form of the tyrosine kinase receptor.  It does not bind EGF.  EGFRvIII is specifically expressed on the cell surface of glioblastoma tumors and potentially other tumors; its expression is implicated in cell survival, tumor progression, and tumor migration.",
      "therapeuticindications_text": "Oncology: Glioblastoma",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": ["MET-002587"],
      "idelisa": "MET-002582",
      "chargeassay": "MET-002588",
      "sec": "MET-001381",
      "rcesds": "MET-001648",
      "titer": "MET-000195",
      "chopelisa": "MET-000180",
      "proaelisa": "MET-001363",
      "bioassayLink": ["http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8125aaa4/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d81134d35"],
      "idelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d81254c9c/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d8111d20e",
      "chargeassayLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d813d638c/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d81134f15",
      "secLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d815b2683/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d80179f9e",
      "rcesdsLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d819ee91b/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d802016e4",
      "titerLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d81177033/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d80114fbe",
      "chopelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8219023e/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d80114d79",
      "proaelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8256d09f/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d801675bf",
      "process_lead": "John Moscariello",
      "analytical_lead": "Amanda Miller - Wesley Wang",
      "formulation_lead": "Shon Crampton",
      "upstream_lead": "Pauline Smidt ",
      "downstream_lead": "Joy Adiletta",
      "fileLink": "",
      "allfilters": "tile adc active fih igg1 kappalc oncology"
    },
    {
      "molecule_name": "AMG 601",
      "status_text": "Inactive",
      "stage_text": "FIH",
      "tile_icon": "igg2lambda.svg",
      "alternate_names": "Anti-IL18 Antibody",
      "molecule_illustration": "amg601.png",
      "pstformed": "8/2004",
      "pstraw": "200408",
      "class1": "IgG2",
      "class2": "Lambda LC",
      "modality": "Monoclonal Antibody",
      "extinctioncoeff": "1.5",
      "peptidemw": "143,255",
      "pi": "8.2",
      "summary_text": "The protein consists of two heavy chains and two light chains. It is predicted that the disulfide structure follows that of other IgG2 molecules with 12 intra-chain disulfides and 6 inter-chain disulfides, with two between the heavy and light chains and the remainder in the hinge region between heavy chains. A presumed single site of glycosylation on each of the heavy chains is shown.",
      "heavychain": "EVQLVESGGGVVQPGRSLRLSCAASGFTFSGYGMHWVRQAPGKGLEWVAVISNDGSKKYYSDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGSSSIWLTSALNLWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": "SSELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVISAKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCASRNGWNHVVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS",
      "heavychain_image": "hc_amg601.png",
      "lightchain_image": "lc_amg601.png",
      "sequence_legend": "%$*#",
      "formulation_text": "10 mM sodium acetate, 9% (w/v) sucrose, 0.004% (w/v) polysorbate 20,  pH 5.2",
      "target_text": "AMG601 binds to the extracellular domain of the IL-18 receptor preventing IL-18 binding thus inhibiting innate and adaptive inflammatory response through this cytokine.",
      "therapeuticindications_text": "Rheumatoid arthritis, Chron’s disease, psoriasis, multiple sclerosis",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": [""],
      "idelisa": "",
      "chargeassay": "",
      "sec": "",
      "rcesds": "",
      "titer": "AWA-AS-M06",
      "chopelisa": "AWA-AS-M05",
      "proaelisa": "AWA-AS-M04",
      "bioassayLink": [""],
      "idelisaLink": "",
      "chargeassayLink": "",
      "secLink": "",
      "rcesdsLink": "",
      "titerLink": "",
      "chopelisaLink": "",
      "proaelisaLink": "",
      "process_lead": "Ganesh Vedantham",
      "analytical_lead": "Randal Bass",
      "formulation_lead": "",
      "upstream_lead": "Allison Bianchi",
      "downstream_lead": "Ganesh Vedantham",
      "fileLink": "",
      "allfilters": "tile monoclonal inactive fih igg2 lambdalc rheumatoidarthritis psoriasis multiplesclerosis"
    },
    {
      "molecule_name": "AMG 655",
      "status_text": "Inactive",
      "stage_text": "Post-CPD",
      "tile_icon": "igg1kappa.svg",
      "alternate_names": "Conatumumab, Anti-TR2 Antibody",
      "molecule_illustration": "amg655.png",
      "pstformed": "2/2004",
      "pstraw": "200402",
      "class1": "IgG1",
      "class2": "Kappa LC",
      "modality": "Monoclonal Antibody",
      "extinctioncoeff": "1.5",
      "peptidemw": "145,612",
      "pi": "8.9",
      "summary_text": "Anti-TR2 (IgG1) is composed of two heavy chains, and two light chains.  There should be 12 intra-molecular disulfide bonds, and 4 inter-molecular disulfide bonds.  The cysteine parings in the figure are those expected for IgG1 antibodies. This antibody is glycosylated on the 2nd constant domain of the heavy chain (N302 linked glycan).",
      "heavychain": "QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYFWSWIRQLPGKGLEWIGHIHNSGTTYYNPSLKSRVTISVDTSKKQFSLRLSSVTAADTAVYYCARDRGGDYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": "EIVLTQSPGTLSLSPGERATLSCRASQGISRSYLAWYQQKPGQAPSLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFGSSPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC",
      "heavychain_image": "hc_amg655.png",
      "lightchain_image": "lc_amg655.png",
      "sequence_legend": "%$*#",
      "formulation_text": "10 mM sodium glutamate, 9% sucrose, 0.006% polysorbate 20, pH 5.2",
      "target_text": "AMG655 targets TRAIL R2 (TNF Related Apoptosis Inducing  Ligand Receptor 2). It causes activation of the receptor cytoplasmic death domains and signals for apoptosis. About 2/3 of transformed cell lines respond to TR2 activation, while most normal cells are resistant to TR2 mediated apoptosis.",
      "therapeuticindications_text": "Oncology: Colorectal, NSCLC, breast cancers and Mutiple Myeloma",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": ["MET-001162"],
      "idelisa": "",
      "chargeassay": "MET-001150",
      "sec": "MET-001151",
      "rcesds": "MET-001172",
      "titer": "A01735",
      "chopelisa": "A01723",
      "proaelisa": "A01727",
      "bioassayLink": ["http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d815e01d0/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d8011887a"],
      "idelisaLink": "",
      "chargeassayLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d80ee253e/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d801187f9",
      "secLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d80c8fdf2/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d80118801",
      "rcesdsLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d80faa165/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d801188da",
      "titerLink": "",
      "chopelisaLink": "",
      "proaelisaLink": "",
      "process_lead": "Art Hewig",
      "analytical_lead": "Wes Wang",
      "formulation_lead": "Matthew Fesinmeyer",
      "upstream_lead": "Sean Davern",
      "downstream_lead": "Art Hewig",
      "fileLink": "",
      "allfilters": "tile monoclonal postcpd inactive igg1 kappalc oncology multiplemyeloma"
    },
    {
      "molecule_name": "AMG 753",
      "status_text": "Inactive",
      "stage_text": "FIH",
      "tile_icon": "fusion.png",
      "alternate_names": "Tek delta Fc fusion protein",
      "molecule_illustration": "amg753.png",
      "pstformed": "9/2003",
      "pstraw": "200309",
      "class1": "",
      "class2": "",
      "modality": "Fusion Protein",
      "extinctioncoeff": "1.2",
      "peptidemw": "151,945",
      "pi": "5.3",
      "summary_text": "AMG753 (TEK delta Fc) is a dimeric fusion protein consisting most of the extra cellular ligand-binding portion of the human Tek/Tie-2 (Angiopoietin receptor) linked to the Fc portion of human IgG1. The Fc component of the molecule contains the hinge region, the CH2 and CH3 domains. The two monomers are covalently linked through disulfide bonds in the Fc hinge region. Each monomer contains 682 amino acids. There are 14 disulfide bonds in the receptor domain, 3 inter-chain disulfide bonds in the hinge region and 2 disulfide bonds in the Fc domain. There are six N-link glycosylation sites in a monomer, five are in the receptor domain, and one is in the Fc domain. Five of the six glycosylation sites are completely occupied, and one is about 95% occupied. The C-terminal lysine is 90% removed. TEK delta Fc is produced in a Chinese hamster ovary mammalian cell expression system",
      "heavychain": "AMDLILINSLPLVSDAETSLTCIASGWRPHEPITIGRDFEALMNQHQDPLEVTQDVTREWAKKVVWKREKASKINGAYFCEGRVRGEAIRIRTMKMRQQASFLPATLTMTVDKGDNVNISFKKVLIKEEDAVIYKNGSFIHSVPRHEVPDILEVHLPHAQPQDAGVYSARYIGGNLFTSAFTRLIVRRCEAQKWGPECNHLCTACMNNGVCHEDTGECICPPGFMGRTCEKACELHTFGRTCKERCSGQEGCKSYVFCLPDPYGCSCATGWKGLQCNEACHPGFYGPDCKLRCSCNNGEMCDRFQGCLCSPGWQGLQCEREGIPRMTPKIVDLPDHIEVNSGKFNPICKASGWPLPTNEEMTLVKPDGTVLHPKDFNHTDHFSVAIFTIHRILPPDSGVWVCSVNTVAGMVEKPFNISVKVLPKPLNAPNVIDTGHNFAVINISSEPYFGEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": "%$*#",
      "heavychain_image": "hc_amg753.png",
      "lightchain_image": "%$*#",
      "sequence_legend": "legend_amg753.png",
      "formulation_text": "10mM sodium phosphate, 140mM sodium chloride, pH 7.4",
      "target_text": "AMG753 is a soluble form of the receptor, Tek/Tie-2. It binds to angiopoietins and inhibits neovessel formation in tumors, ovary, ischemic heart and retina in animal models.",
      "therapeuticindications_text": "Oncology: Angiogenesis-mediated ocular disorders, Wet-Age Related macular degeneration, Proliferative Diabetic retinopathy",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": ["T-2030"],
      "idelisa": "",
      "chargeassay": "T-2037",
      "sec": "T-2039",
      "rcesds": "",
      "titer": "",
      "chopelisa": "T-2034",
      "proaelisa": "T-2035",
      "bioassayLink": [""],
      "idelisaLink": "",
      "chargeassayLink": "",
      "secLink": "",
      "rcesdsLink": "",
      "titerLink": "",
      "chopelisaLink": "",
      "proaelisaLink": "",
      "process_lead": "Abhinav Shukla",
      "analytical_lead": "Yihong Han",
      "formulation_lead": "Tim Osslund",
      "upstream_lead": "Virginia Price",
      "downstream_lead": "Sean Han",
      "fileLink": "",
      "allfilters": "tile fusion inactive fih oncology"
    },
     {
      "molecule_name": "AMG 780",
      "status_text": "Active in Development",
      "stage_text": "CFD",
      "tile_icon": "igg2kappa.svg",
      "alternate_names": "Anti angiopoietin antibody",
      "molecule_illustration": "amg780.png",
      "pstformed": "7/2007",
      "pstraw": "200707",
      "class1": "IgG2",
      "class2": "Kappa LC",
      "modality": "Monoclonal Antibody",
      "extinctioncoeff": "1.4",
      "peptidemw": "146,094",
      "pi": "7.4",
      "summary_text": "Anti angiopoietin mAb is composed of two heavy chains, and two light chains.  There are 12 intramolecular disufide bonds, and six intermolecular disulfide bonds.  Anti angiopoietin has a single glycosylation site located on the 2nd constant domain of each heavy chain (N298 glycan).",
      "heavychain": "EVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDLLDYDLLTGYGYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": "DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSHGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC",
      "heavychain_image": "hc_amg780.png",
      "lightchain_image": "lc_amg780.png",
      "sequence_legend": "legend_amg780.png",
      "formulation_text": "10 mM sodium acetate, 9% sucrose, 0.004% polysorbate 20, pH 5.2",
      "target_text": "AMG 780 is directed towards the angiopoetin 2 ligand to the Tie 2 receptor. The target rationale is to inhibit and prevent bloodvessel formation for tumor growth and progression",
      "therapeuticindications_text": "Oncology: Solid Tumor",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": ["MET-001828"],
      "idelisa": "",
      "chargeassay": "MET-001673",
      "sec": "MET-001391",
      "rcesds": "MET-001648",
      "titer": "MET-001312",
      "chopelisa": "MET-000180",
      "proaelisa": "MET-001363",
      "bioassayLink": ["http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82177b42/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d803eb7d3"],
      "idelisaLink": "",
      "chargeassayLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d804310b2/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d8030de8f",
      "secLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d803bbf7d/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d8018355d",
      "rcesdsLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d819ee91b/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d802016e4",
      "titerLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82e941ae/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d80119cfa",
      "chopelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8219023e/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d80114d79",
      "proaelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8256d09f/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d801675bf",
      "process_lead": "Jette Wypych ",
      "analytical_lead": "Jette Wypych ",
      "formulation_lead": "Tim Osslund",
      "upstream_lead": "",
      "downstream_lead": "",
      "fileLink": "",
      "allfilters": "tile monoclonal igg2 kappalc active cfd oncology"
    },
    {
      "molecule_name": "AMG 785",
      "status_text": "Active in Development",
      "stage_text": "Post-CPD",
      "tile_icon": "igg2kappa.svg",
      "alternate_names": "Anti Sclerostin mAb",
      "molecule_illustration": "amg785.png",
      "pstformed": "5/2005",
      "pstraw": "200505",
      "class1": "IgG2",
      "class2": "Kappa LC",
      "modality": "Monoclonal Antibody",
      "extinctioncoeff": "1.5",
      "peptidemw": "145,622",
      "pi": "6.8",
      "summary_text": "AMG 785 is composed of two heavy chains and two light chains.  Disulfide bonds are shown in thin lines.  There is a single glycosylation site located on the second constant domain of each heavy chain (N299).",
      "heavychain": "EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMHWVRQAPGQGLEWMGEINPNSGGAGYNQKFKGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARLGYDDIYDDWYFDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": "DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLLSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGDTLPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC",
      "heavychain_image": "hc_amg785.png",
      "lightchain_image": "lc_amg785.png",
      "sequence_legend": "legend_amg785.png",
      "formulation_text": "55 mM acetate, 13 mM calcium, 6% sucrose, 0.006% polysorbate 20, pH 5.2",
      "target_text": "AMG 785 is a humanized monoclonal antibody targeting at sclerostin, a negative regulator of bone growth. It stimulates the cells (osteoblasts) that actively make the bones.",
      "therapeuticindications_text": "Fracture healing and post-menupausal osteoporosis",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": ["MET-002596"],
      "idelisa": "MET-002373",
      "chargeassay": "MET-002693",
      "sec": "MET-002694",
      "rcesds": "MET-002612",
      "titer": "MET-002638",
      "chopelisa": "MET-002687",
      "proaelisa": "MET-002616",
      "bioassayLink": ["http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8235cf3f/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d811abfe4"],
      "idelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d828d6d21/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d807d6ecd",
      "chargeassayLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d828d5278/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d81499ce0",
      "secLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d81668874/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d8149a160",
      "rcesdsLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82b9f8a3/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d8122fb82",
      "titerLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82820328/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d812e6ad0",
      "chopelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82509167/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d8146938e",
      "proaelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8256d0bd/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d81252c0b",
      "process_lead": "Sekhar Kanapuram",
      "analytical_lead": "Tian Wang",
      "formulation_lead": "SungAe Park",
      "upstream_lead": "Sean Cole",
      "downstream_lead": "Oliver Kaltenbrunner",
      "fileLink": "",
      "allfilters": "tile monoclonal igg2 kappalc active postcpd fracturehealing postmenopausalosteoporosis"
    },
    {
      "molecule_name": "AMG 820",
      "status_text": "On Hold",
      "stage_text": "FIH",
      "tile_icon": "igg2kappa.svg",
      "alternate_names": "Anti human c-fms",
      "molecule_illustration": "amg820.png",
      "pstformed": "4/2006",
      "pstraw": "200604",
      "class1": "IgG2",
      "class2": "Kappa LC",
      "modality": "Monoclonal Antibody",
      "extinctioncoeff": "1.6",
      "peptidemw": "146,569",
      "pi": "6.9",
      "summary_text": "AMG 820 is a full length immunoglobulin directed against colony stimulating factor-1 (CSF-1).  The molecule is a heterotetramer consisting of 2 heavy chains (HC) of the lgG2 subclass and 2 light chains (LC) of the kappa subclass, which are covalently linked through disulfide bonds.   The schematic structure shown is a canonical structure for an IgG2.  There are 12 intra chain disulfide bonds and 6 inter chain disulfide bonds.  Each HC contains an N-linked glycan at the canonical glycosylation site located on the 2nd constant domain of the heavy chain (N296).",
      "heavychain": "QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARESWFGEVFFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": "DIVMTQSPDSLAVSLGERATINCKSSQSVLDSSDNKNYLAWYQQKPGQPPKLLIYWASNRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSDPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC",
      "heavychain_image": "hc_amg820.png",
      "lightchain_image": "lc_amg820.png",
      "sequence_legend": "%$*#",
      "formulation_text": "10mM sodium acetate, 9% sucrose, 0.004% polysorbate 20, pH 5.2",
      "target_text": "AMG820 is a fully human anti-human c-fms antibody that binds the c-fms receptor and prevents binding of CFS-1.The underlying biology of this project depends on eliminating tumor associated macrophages (TAMs) by blocking the CSF-1/c-fms axis.   CSF-1 is thought to be the primary growth factor for TAMs. TAMs can potentially support tumor growth and survival through their ability to produce many pro-tumor and pro-angiogenic proteins within the tumor micro-environment. A molecule that could remove TAMs and thus remove this source of growth and angiogenic factors would be expected to reduce tumor cell survival.  CD30L antibody binds to native human and cynomolgus CD30L and blocks the biological function of both ligands in cell-based assays.",
      "therapeuticindications_text": "Oncology",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": ["A01738"],
      "idelisa": "",
      "chargeassay": "A01730",
      "sec": "A01729",
      "rcesds": "A01731",
      "titer": "A01735",
      "chopelisa": "A01631",
      "proaelisa": "A01630",
      "bioassayLink": [""],
      "idelisaLink": "",
      "chargeassayLink": "",
      "secLink": "",
      "rcesdsLink": "",
      "titerLink": "",
      "chopelisaLink": "",
      "proaelisaLink": "",
      "process_lead": "Jeff McGrew",
      "analytical_lead": "Theresa Martinez",
      "formulation_lead": "Gerd Kleemann",
      "upstream_lead": "Ray Davis",
      "downstream_lead": "Joanne Reeder",
      "fileLink": "",
      "allfilters": "tile monoclonal igg2 kappalc onhold fih oncology"
    },

    {
      "molecule_name": "AMG 827",
      "status_text": "Active in Development",
      "stage_text": "Post-CPD",
      "tile_icon": "igg2kappa.svg",
      "alternate_names": "Brodalumab",
      "molecule_illustration": "amg827.png",
      "pstformed": "",
      "pstraw": "0",
      "class1": "IgG2",
      "class2": "Kappa LC",
      "modality": "Monoclonal Antibody",
      "extinctioncoeff": "1.5",
      "peptidemw": "143,775",
      "pi": "8.8",
      "summary_text": "AMG 827 is a full-length, fully-human monoclonal antibody produced in CHO cells.  It is a heterotetramer consisting of two heavy chains of the IgG2 subclass and two light chains of the kappa subclass.  There are 12 intramolecular disulfide bonds, and six intermolecular disulfide bonds.  AMG 827 has a single glycosylation site located on the 2nd constant domain of each heavy chain (N292).",
      "heavychain": "QVQLVQSGAEVKKPGASVKVSCKASGYTFTRYGISWVRQAPGQGLEWMGWISTYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARRQLYFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": "EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWFQQKPGQAPRPLIYDASTRATGVPARFSGSGSGTDFTLTISSLQSEDFAVYYCQQYDNWPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC",
      "heavychain_image": "hc_amg827.png",
      "lightchain_image": "lc_amg827.png",
      "sequence_legend": "legend_amg827.png",
      "formulation_text": "10 mM glutamate, 3% (w/v) proline, 0.01% (w/v) polysorbate 20, pH 4.8",
      "target_text": "AMG 827 targets IL-17 Receptor A (IL-17RA), inhibiting subsequent binding of the IL-17R heteropolymer  to multiple isoforms of the inflammatory cytokine IL-17.  Inhibition of this pathway is thought to suppress subsequent pro-inflammatory responses.",
      "therapeuticindications_text": "Psoriasis",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": ["MET-002646"],
      "idelisa": "MET-002523",
      "chargeassay": "MET-002619",
      "sec": "MET-002660",
      "rcesds": "MET-002661",
      "titer": "MET-000610",
      "chopelisa": "MET-002685",
      "proaelisa": "MET-002617",
      "bioassayLink": ["http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d820a61b6/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d81305f88"],
      "idelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82909935/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d80e11d5a",
      "chargeassayLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82d5aac5/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d8127b336",
      "secLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82271b03/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d8137f816",
      "rcesdsLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d822710e0/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d8137f8e6",
      "titerLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82ebd677/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d801161f7",
      "chopelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d8219295a/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d81464bbc",
      "proaelisaLink": "http://edmquality.amgen.com/edmquality/drl/objectId/09014b2d82a17f24/versionLabel/CURRENT/format/pdf/chronicleId/09014b2d81266584",
      "process_lead": "Jeff Plomer",
      "analytical_lead": "Eric Meinke",
      "formulation_lead": "Nitin Rathore",
      "upstream_lead": "",
      "downstream_lead": "",
      "fileLink": "",
      "allfilters": "tile monoclonal igg2 kappalc active postcpd psoriasis"
    }, 
    {
      "molecule_name": "AMG 864",
      "status_text": "Inactive",
      "stage_text": "FIH",
      "tile_icon": "igg1kappa.svg",
      "alternate_names": "Anti-amyloid",
      "molecule_illustration": "amg864.png",
      "pstformed": "",
      "pstraw": "0",
      "class1": "IgG1",
      "class2": "Kappa LC",
      "modality": "Monoclonal Antibody",
      "extinctioncoeff": "1.5",
      "peptidemw": "147,341",
      "pi": "8.9",
      "summary_text": "Based on knowledge of IgG1 structure, the protein is assumed to be composed of two heavy chains, and two light chains.  There are 12 intra-molecular disufide bonds, and 4 inter-molecular disulfide bonds.  AMG864 is glycosylated, presumably in the CH2 domain.",
      "heavychain": "QVTLKESGPALVKPTQTLTLTCTFSGFSLRTSGMGVGWIRQPPGKALEWLAHIWWDDDKSYNPSLKSQLTISKDTSKNQVVLTMTNMDPVDTATYYCARRNYYYDDYFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": "DVLMTQSPLSLPVTLGQPASISCRSSQSIVHSNGNTYLEWYLQRPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPLTFGAGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC",
      "heavychain_image": "hc_amg864.png",
      "lightchain_image": "lc_amg864.png",
      "sequence_legend": "%$*#",
      "formulation_text": "50mM sodium acetate, 5% sorbitol, 0.004% polysorbate 20, pH 5.2",
      "target_text": "AMG 864 is an antibody against amyloid fibrils that causes the regression of amyloid plaques through the action of microglial cells",
      "therapeuticindications_text": "Alzheimer’s disease",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": [""],
      "idelisa": "",
      "chargeassay": "",
      "sec": "",
      "rcesds": "",
      "titer": "",
      "chopelisa": "",
      "proaelisa": "",
      "bioassayLink": [""],
      "idelisaLink": "",
      "chargeassayLink": "",
      "secLink": "",
      "rcesdsLink": "",
      "titerLink": "",
      "chopelisaLink": "",
      "proaelisaLink": "",
      "process_lead": "Bob Bailey",
      "analytical_lead": "Bob Bailey",
      "formulation_lead": "Deirdre Piedmont",
      "upstream_lead": "Martin Allen",
      "downstream_lead": "Hassan Madani",
      "fileLink": "",
      "allfilters": "tile monoclonal igg1 kappalc inactive fih alzheimers"
    },
    {
      "molecule_name": "AMG 891",
      "status_text": "Inactive",
      "stage_text": "FIH",
      "tile_icon": "igg2lambda.svg",
      "alternate_names": "Anti-Hepcidin Antibody",
      "molecule_illustration": "amg891.png",
      "pstformed": "5/2007",
      "pstraw": "200705",
      "class1": "IgG2",
      "class2": "Lambda LC",
      "modality": "Monoclonal Antibody",
      "extinctioncoeff": "1.6",
      "peptidemw": "146,339",
      "pi": "7.2",
      "summary_text": "Based on the putative structure of IgG2 antibodies, the protein is likely composed of two heavy chains, and two light chains.  There should be 12 intra-molecular disulfide bonds, and 6 inter-molecular disulfide bonds.  Indicated cysteine pairings in hinge region are those expected for IgG2 antibodies.  AMG 891 has one N-linked glycosylation site at N-297 in the second constant domain of the heavy chain (CH2).",
      "heavychain": "QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYAESNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARAQEGIAPDAFDIWGQGTMVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": "YELTQPPSVSVSPGQTATITCSGDKLGERYASWYQQRPGQSPVLVIYQDIKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYFCQAWYSSTNVLFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS",
      "heavychain_image": "hc_amg891.png",
      "lightchain_image": "lc_amg891.png",
      "sequence_legend": "legend_amg891.png",
      "formulation_text": "10 mM sodium acetate, 9% sucrose, 0.004% polysorbate 20, pH 5.2",
      "target_text": "Hepcidin is 25 aa peptide hormone produced by the liver, that appears to be the master regulator of iron homeostasis in humans and other mammals.  Hepcidin can be induced by high iron levels and by inflammation.   Ferroportin is the hepcidin receptor (the gatekeeper of iron release). Hepcidin binds to ferroportin and stimulates ferroportin internalization and degradation, leading to anemia. AMG891 is a fully human anti-human antibody that binds the hepcidin and prevents/cures anemia.",
      "therapeuticindications_text": "Anemia",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": [""],
      "idelisa": "",
      "chargeassay": "",
      "sec": "",
      "rcesds": "",
      "titer": "",
      "chopelisa": "",
      "proaelisa": "",
      "bioassayLink": [""],
      "idelisaLink": "",
      "chargeassayLink": "",
      "secLink": "",
      "rcesdsLink": "",
      "titerLink": "",
      "chopelisaLink": "",
      "proaelisaLink": "",
      "process_lead": "",
      "analytical_lead": "Boxu Yan",
      "formulation_lead": "Gerd Kleeman",
      "upstream_lead": "",
      "downstream_lead": "",
      "fileLink": "",
      "allfilters": "tile monoclonal igg2 lambdalc inactive fih anemia"
    },
    {
      "molecule_name": "AMG 954",
      "status_text": "Marketed Product",
      "stage_text": "Marketed Product",
      "tile_icon": "igg2kappa.svg",
      "alternate_names": "Vectibix, panitumumab, Anti- EGFr",
      "molecule_illustration": "amg954.png",
      "pstformed": "",
      "pstraw": "0",
      "class1": "IgG2",
      "class2": "Kappa LC",
      "modality": "Monoclonal Antibody",
      "extinctioncoeff": "1.4",
      "peptidemw": "144,043",
      "pi": "6.6",
      "summary_text": "The protein is composed of two heavy chains and two light chains. There are 12 intra-heavy and intra-light chains disulfide bonds, four inter-heavy chains, and two inter-heavy and light chains disulfide bonds. AMG 954 has one glycosylation site located in the CH2 domain of the heavy chain (N295 glycan).",
      "heavychain": "QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGLEWIGHIYYSGNTNYNPSLKSRLTISIDTSKTQFSLKLSSVTAADTAIYYCVRDRVTGAFDIWGQGTMVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": "DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQHFDHLPLAFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC",
      "heavychain_image": "hc_amg954.png",
      "lightchain_image": "lc_amg954.png",
      "sequence_legend": "legend_amg954.png",
      "formulation_text": "50 mM sodium acetate, 100 mM sodium chloride, pH 5.8",
      "target_text": "AMG 954 binds to Epidermal Growth Factor receptor (EGFr) to inhibit tumor cell growth.",
      "therapeuticindications_text": "Oncology: 3rd/4th line colorectal cancer (CRC). Renal cell cancer (RCC), prostate cancer, pancreatic cancer, non-small cell lung cancer (NSCLC), oesophageal/gastroesophageal injuction cancer",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": ["QC-051 (Abgenix)"],
      "idelisa": "",
      "chargeassay": "T-0406",
      "sec": "T-0405",
      "rcesds": "T-0409",
      "titer": "",
      "chopelisa": "T-0412",
      "proaelisa": "T-0404",
      "bioassayLink": [""],
      "idelisaLink": "",
      "chargeassayLink": "",
      "secLink": "",
      "rcesdsLink": "",
      "titerLink": "",
      "chopelisaLink": "",
      "proaelisaLink": "",
      "process_lead": "Ralph Klinke",
      "analytical_lead": "Amy Guo",
      "formulation_lead": "Jeannine Wong",
      "upstream_lead": "",
      "downstream_lead": "",
      "fileLink": "",
      "allfilters": "tile monoclonal igg2 kappalc marketedproduct oncology"
    }, {
      "molecule_name": "Enbrel",
      "status_text": "Marketed Product",
      "stage_text": "Marketed Product",
      "tile_icon": "fusion.png",
      "alternate_names": "TNFR:Fc fusion protein",
      "molecule_illustration": "enbrel.png",
      "pstformed": "",
      "pstraw": "0",
      "class1": "",
      "class2": "",
      "modality": "Fusion Protein",
      "extinctioncoeff": "1.1",
      "peptidemw": "102,418",
      "pi": "5.5",
      "summary_text": "ENBREL (etanercept) is a dimeric fusion protein consisting of the extracellular ligand binding portion of the human 75 kilo Dalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids with both N- and O-glycosylation sites. Apparent molecular weight of glycsylated Etanercept is ~150 kilo Daltons. ",
      "heavychain": "LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK",
      "lightchain": "%$*#",
      "heavychain_image": "hc_enbrel.png",
      "lightchain_image": "%$*#",
      "sequence_legend": "%$*#",
      "formulation_text": "10 mM Tris(hydroxymethyl)-aminomethane, pH 7.4, 4% mannitol, 1% sucrose",
      "target_text": "Etanercept inhibits binding of both TNFa and TNFb  (lymphotoxin alpha [LTa] to cell surface TNFRs, rendering TNF biologically inactive.",
      "therapeuticindications_text": "Rheumatoid Arthritis, Polyarticular-Course Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Psoriasis.",
      "milestones_text": [],
      "issueschallenges_text": "",
      "bioassay": [""],
      "idelisa": "",
      "chargeassay": "",
      "sec": "",
      "rcesds": "",
      "titer": "",
      "chopelisa": "",
      "proaelisa": "",
      "bioassayLink": [""],
      "idelisaLink": "",
      "chargeassayLink": "",
      "secLink": "",
      "rcesdsLink": "",
      "titerLink": "",
      "chopelisaLink": "",
      "proaelisaLink": "",
      "process_lead": "Sean Kelley",
      "analytical_lead": "Letha Chemmalil",
      "formulation_lead": "Monica Pallitto",
      "upstream_lead": "Eli Kraus",
      "downstream_lead": "Sam Trejo",
      "fileLink": "",
      "allfilters": "tile fusion arthritis marketedproduct rheumatoidarthritis psoriaticarthritis psoriasis"
    }
  ];